var title_f41_31_42480="Terminal bone tuft resorption";
var content_f41_31_42480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Terminal bone tuft resorption in scleroderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Marked terminal bone tuft resorption in a patient with limited cutaneous systemic sclerosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_31_42480=[""].join("\n");
var outline_f41_31_42480=null;
var title_f41_31_42481="Cardiac amyloidosis short axis echocardiogram";
var content_f41_31_42481=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/78037/shaxcaam_conv.mp4?title=Cardiac+amyloidosis+short+axis+echocardiogram\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cardiac amylodosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 447px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Short axis view from a 2-D echocardiogram shows concentric left ventricular hypertrophy and thickened mitral valve leaflets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_31_42481=[""].join("\n");
var outline_f41_31_42481=null;
var title_f41_31_42482="Severe atopic dermatitis";
var content_f41_31_42482=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe atopic dermatitis in a 12-year-old girl showing in the typical location of the popliteal fossae. Note the oozing of serous fluid from the most involved areas, plus the papular component and erythema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Walsh, MD, FRPCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_31_42482=[""].join("\n");
var outline_f41_31_42482=null;
var title_f41_31_42483="Inosine pranobex: Patient drug information";
var content_f41_31_42483=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Inosine pranobex: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/34/8739?source=see_link\">",
"     see \"Inosine pranobex: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16144138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Imunovir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F16349039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4202415",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat subacute sclerosing panencephalitis (SSPE).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F16349040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4202416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to inosine pranobex or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may interact with other drugs or health problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F16349041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F16349042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor if any of these side effects or any other side effects bother you:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F16349043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these side effects:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to Health Canada's Canada Vigilance Program at 1-866-234-2345.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F16349044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696083",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug as ordered by your doctor. Read and follow the dosing on the label closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F16349045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F16349046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check with your pharmacist about how to throw out unused drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F16349047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88726 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.22.229.50-C760863B48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_31_42483=[""].join("\n");
var outline_f41_31_42483=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16144138\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16349039\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16349040\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16349041\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16349042\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16349043\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16349044\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16349045\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16349046\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16349047\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/34/8739?source=related_link\">",
"      Inosine pranobex: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_31_42484="Normal postoperative CT scan after gastric bypass";
var content_f41_31_42484=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Normal postoperative CT scan after gastric bypass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This computed tomography (CT) scan after gastric bypass shows the gastrojejunostomy and Roux limb anterior to the gastric remnant. The Roux limb is medial to the biliopancreatic (BP) limb. The remnant contains some fluid. This is a normal study of an antegastric antecolic gastric bypass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_31_42484=[""].join("\n");
var outline_f41_31_42484=null;
var title_f41_31_42485="colorec CA resection margin";
var content_f41_31_42485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circumferential resection margin for colorectal cancers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 464px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_31_42485=[""].join("\n");
var outline_f41_31_42485=null;
var title_f41_31_42486="Normal values for GFR in men and women";
var content_f41_31_42486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F73824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F73824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 656px\">",
"   <div class=\"ttl\">",
"    Normal values for GFR in men and women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 636px; height: 436px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal values for inulin clearance are shown for men (panel A) and women (panel B) of various ages, with the GFR measured as the urinary clearance of inulin. A GFR &lt;60 mL/min/1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    is the threshold for the definition of chronic kidney disease. Solid lines represent the mean value of GFR per decade of age, and dashed lines represent the value 1 SD from the mean value of GFR per decade of age.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Wesson L. Physiology of the Human Kidney, Grune &amp; Stratton, New York 1969. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_31_42486=[""].join("\n");
var outline_f41_31_42486=null;
var title_f41_31_42487="Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus";
var content_f41_31_42487=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/31/42487/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/31/42487/contributors\">",
"     Lois Jovanovic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/31/42487/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/31/42487/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/31/42487/contributors\">",
"     Michael F Greene, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/31/42487/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/31/42487/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/31/42487/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prepregnancy planning and early identification and treatment of diabetes-related morbidity are essential for optimizing maternal and fetal outcome in women with type 1 and type 2 diabetes. Women with pregestational diabetes mellitus should be well informed about the importance of a planned pregnancy and should work closely with their clinician to optimize their health status prior to conception. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/27/36281?source=see_link\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increasing number of women of child-bearing age with undiagnosed, and thus untreated, type 2 diabetes is a concern, as these women may not be in optimum health when they become pregnant and will not receive treatment until identified as a result of diabetes screening during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9210?source=see_link\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MATERNAL EVALUATION AND INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete history and physical examination should be performed at the preconception visit. This evaluation should include information on the duration and type of diabetes, history of acute complications (infections, ketoacidosis, severe hypoglycemia) and chronic complications (retinopathy, nephropathy, neuropathy, hypertension, cardiovascular disease), current and past glucose management, physical activity, comorbid medical conditions, gynecologic and obstetric history, and family issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/2\">",
"     2",
"    </a>",
"    ]. It is useful to involve a diabetes educator and a registered dietitian and include the woman's partner.",
"   </p>",
"   <p>",
"    A checklist of issues to address during prepregnancy evaluation of women with diabetes mellitus is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef79625 \" href=\"mobipreview.htm?35/33/36380\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycemic control plays an important role in reducing the frequency of fetal and neonatal complications. Glycated hemoglobin (A1C) values, which reflect the average blood glucose concentration over the previous 8 to 12 weeks, are useful in evaluating a woman's glycemic control before conception and throughout pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2266212\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;To be most effective, glycemic control needs to be achieved preconceptionally. Therefore, a major goal of preconception care of women with diabetes is to evaluate glycemic control and recommend adjustments in diet, medications, and lifestyle, as needed, to achieve euglycemia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis comparing pregnancy outcome and A1C values in diabetic women who received preconception care to those who did not, women who received preconception care had both lower first trimester mean A1C concentrations (mean difference 2.3 percent) and significantly fewer offspring with major congenital anomalies (2.1 versus 6.5 percent, RR 0.36, 95% CI 0.22-0.59) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/3\">",
"       3",
"      </a>",
"      ]. The risk of combined major and minor anomalies was also lower in these women (RR 0.32, 95% CI 0.17-0.59).",
"     </li>",
"     <li>",
"      A subsequent audit of pregnancy outcome in Scottish women with pregestational diabetes revealed that documentation of achievement of an optimal A1C value prior to discontinuation of contraception was the marker associated with the lowest rate of adverse pregnancy outcome (OR 0.2, 95% CI 0.06-0.67) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/4\">",
"       4",
"      </a>",
"      ]. Adverse outcome included miscarriage, major congenital anomaly, and perinatal death. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=see_link\">",
"       \"Estimation of blood glucose control in diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women with Type 2 diabetes on oral anti-hyperglycemic agents should be switched to insulin therapy preconceptionally so that their glycemic control is not jeopardized during the process of switching therapies early in pregnancy. Our program for managing glucose levels preconceptionally and during pregnancy in women with diabetes is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20794?source=see_link\">",
"     \"Medical management of type 1 and type 2 diabetes mellitus in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2266094\">",
"    <span class=\"h3\">",
"     Target",
"    </span>",
"    &nbsp;&mdash;&nbsp;National organizations have recommended prepregnancy A1C targets of &lt;6.1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/5\">",
"     5",
"    </a>",
"    ] and &lt;7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], if safely achievable. This level of glycemic control is associated with a low rate of miscarriage, congenital malformations, and preeclampsia. The standardized mean A1C in nondiabetics is 5 percent, with an upper limit of 6.1 percent for almost all A1C assays in the United States.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High A1C values early in pregnancy are linked to an increased risk of miscarriage and congenital malformations (",
"      <a class=\"graphic graphic_figure graphicRef67498 \" href=\"mobipreview.htm?43/27/44477\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. A review of studies evaluating the relationship between periconceptional maternal A1C concentration and congenital anomalies in offspring found that for each 1 SD unit increase in A1C above normal, the odds of congenital anomalies increased significantly: OR 1.2 (95% CI 1.1-1.4) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/11\">",
"       11",
"      </a>",
"      ]. Of note, these studies focused on women with type 1 diabetes and many of the studies were performed when A1C was not standardized.",
"     </li>",
"     <li>",
"      In a study of women with type 1 diabetes, the incidence of preeclampsia was lowest in women with optimal glycemic control (A1C &lt;6.1 percent) and rose significantly as A1C increased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In addition to reducing the risk of",
"      <span class=\"nowrap\">",
"       fetal/neonatal",
"      </span>",
"      complications, prospective, randomized clinical trials such as the Diabetes Control and Complications Trial (DCCT), the United Kingdom Prospective Diabetes Study (UKPDS), and the Kumamoto study have demonstrated that intensive therapy aimed at lower levels of glycemia results in decreased rates of retinopathy, nephropathy, and neuropathy in nonpregnant individuals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We attempt to have our patients achieve a A1C level in the lower part of the normal range preconception. In women planning pregnancy, we allow a peak postprandial glucose level as high as 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    one hour after eating; however, as soon as the pregnancy test is positive we attempt to keep the peak glucose level to less than 120",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"   </p>",
"   <p>",
"    Women with pregestational diabetes mellitus and good glycemic control may still have increased rates of pregnancy complications compared to the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. It is possible that near optimal glycemic control (A1C &lt;6.1 percent) is not sufficient to change these outcomes due to the presence of large fluctuations in glucose concentration, both high and low, over the course of the day; this would only be detectable with continuous glucose monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Furthermore, attempts to achieve euglycemia in type 1 diabetics are invariably associated with an increased frequency of hypoglycemic episodes, which may be risky for the mother.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with diabetes who are planning pregnancy should have a comprehensive eye examination (if not performed within the previous 12 months) and be counseled on the risk of development",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progression of diabetic retinopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Routine eye examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with diabetes who become pregnant should have a comprehensive eye examination in the first trimester and close follow-up throughout pregnancy and for one year postpartum.",
"   </p>",
"   <p>",
"    The best strategy for minimizing progression of retinopathy during pregnancy appears to be normalization of glycemic control before pregnancy. Frequent monitoring by a retinal specialist is helpful to look for early worsening of retinopathy as glycemic control improves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/17\">",
"     17",
"    </a>",
"    ]. Laser photocoagulation should be considered for women with severe preproliferative diabetic retinopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link&amp;anchor=H6#H6\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\", section on 'Established retinopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial prepregnancy assessment should document baseline renal function, including protein excretion and serum creatinine concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although many women experience a temporary decline in renal function during gestation, pregnancy per se does not appear to hasten the natural progression to end-stage renal disease for most women; however, this depends upon the initial degree of renal impairment. The risk of permanent decline in renal function is substantially increased in women with a urine creatinine concentration above 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (176",
"    <span class=\"nowrap\">",
"     mumol/L),",
"    </span>",
"    many of whom have more than 2 g of proteinuria per day. These findings can be considered relative contraindications to pregnancy. A creatinine clearance below 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    before pregnancy is associated with a high prevalence of hypertension and fetal wastage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of pregnancy on diabetic nephropathy, the effects of diabetic nephropathy on pregnancy outcome, and management of these patients are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/19/21816?source=see_link\">",
"     \"Pregnancy in women with diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, all antihypertensive drugs should be stopped before conception if the blood pressure remains in the normal range. Although blood pressure goals specifically for pregnant women with diabetes have not been established, we believe the approach should be the same as in nonpregnant women with diabetes. The goal blood pressure varies with certain clinical characteristics. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual antihypertensive agents used in nonpregnant women often are not appropriate in pregnancy because of fetal concerns. For women who are pregnant or planning pregnancy, our preference is to treat elevated blood pressures with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    or a long acting calcium channel blocker (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"     Labetalol",
"    </a>",
"    can be added as either a second or third line treatment. Thiazide diuretics are relatively contraindicated in pregnancy and ACE inhibitors, angiotensin II receptor blockers, and direct renin inhibitors should not be used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Medications to avoid'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for screening for coronary heart disease are the same as in nonpregnant diabetics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Screening for coronary heart disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24970?source=see_link&amp;anchor=H25#H25\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\", section on 'Exercise rMPI in diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Over the long-term, a substantial reduction in cardiovascular mortality can be achieved by stopping smoking, and, when indicated, daily low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and aggressive treatment of hypertension and dyslipidemia. These interventions are also appropriate for pregnant women, except lipid lowering drugs are generally contraindicated in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Reducing the risk of macrovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Medications to avoid",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2266303\">",
"    <span class=\"h3\">",
"     Angiotensin-converting enzyme inhibitors and receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin-converting enzyme (ACE) inhibitors and receptor blockers (ARBs) are contraindicated in pregnancy because they are teratogenic. They generally should be avoided in women of child-bearing age in case of unplanned pregnancy. Possible exceptions are diabetic women with microalbuminuria or overt proteinuria who are well-informed of the risk of conceiving while taking these agents; in these women, an ACE inhibitor can slow progression of the renal disease, making later pregnancy safer. However, the ACE inhibitor should be discontinued when the women starts to attempt to conceive. As an alternative, calcium channel blockers appear to have a similar protective effect on the kidney as ACE inhibitors and are not known to be harmful to the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2266311\">",
"    <span class=\"h3\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although adverse effects have not been proven, statins are best avoided during pregnancy because of limited data on safety, theoretical concerns regarding the role of cholesterol in embryo development, and the lack of demonstrated benefit of treating hyperlipidemia during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link&amp;anchor=H19#H19\">",
"     \"Statins: Actions, side effects, and administration\", section on 'Risks in pregnancy and breastfeeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thyroid disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prepregnancy evaluation should include measurement of serum thyrotropin (TSH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/20\">",
"     20",
"    </a>",
"    ]. We also measure free T4, given the high prevalence of coexistent thyroid disease in these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31414?source=see_link&amp;anchor=H4#H4\">",
"     \"Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus\", section on 'Thyroid screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in nonpregnant diabetics, systematic screening examinations for neuropathic and vascular involvement of the lower extremities and careful inspection of feet may substantially reduce morbidity from foot problems. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Routine foot examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diabetic gastroparesis is usually suspected on clinical grounds based on dyspeptic complaints. Treatment is directed toward alleviating symptoms related to gastric stasis (such as dyspepsia). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24985?source=see_link&amp;anchor=H4#H4\">",
"     \"Diabetic autonomic neuropathy of the gastrointestinal tract\", section on 'Gastroparesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bacteriuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women should be screened for asymptomatic bacteriuria and those with positive test results should be treated to prevent development of pyelonephritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/19/42295?source=see_link&amp;anchor=H12#H12\">",
"     \"Approach to the adult with asymptomatic bacteriuria\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     General issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;General issues related to preconception evaluation and counseling, such as nutrition, supplements, genetic screening, and immunizations, in any women planning pregnancy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/25/16794?source=see_link\">",
"     \"Preconception evaluation and counseling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Folic acid supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Society of Obstetricians and Gynaecologists of Canada, and others, recommend that women at intermediate to high risk of having a child with a neural tube defect (previously affected child, family history of neural tube defect, insulin-requiring diabetes, treatment with valproic acid or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ) take 4 to 5 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    daily beginning at least one month prior to conception and continuing through the first trimester. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5081?source=see_link&amp;anchor=H8#H8\">",
"     \"Folic acid for prevention of neural tube defects\", section on 'High risk women'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists recommends supplementation with a minimum of 0.4 to 0.8 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , with higher doses (4 mg) if there are \"additional risk factors for neural tube defects\". Some clinicians consider pregestational diabetes one such additional risk factor, others believe glucose-mediated neural tube defects probably are not prevented by folate supplementation and therefore additional supplementation is unnecessary.",
"   </p>",
"   <p>",
"    For women with pregestational diabetes, the American Diabetes Association recommends folate intake of 0.6",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in the periconception and prenatal periods through supplementation or fortified food sources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Contraception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with diabetes not ready to have children should receive appropriate contraceptive counseling. There are no contraceptive methods that are specifically contraindicated in women with diabetes; therefore, selection should be based upon the same guidelines that apply to women without diabetes, with some caveats as discussed below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reliable contraception is particularly important for diabetic women as unplanned pregnancy in these patients is associated with an increased risk of miscarriage and congenital malformations if glycemia is not well-controlled.",
"   </p>",
"   <p>",
"    The World Health Organization (",
"    <a class=\"graphic graphic_table graphicRef69329 \" href=\"mobipreview.htm?19/34/20013\">",
"     table 2",
"    </a>",
"    ) and Centers for Disease Control (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"     table 3",
"    </a>",
"    ) recommendations for use of hormonal contraception in women with diabetes are shown in the tables. The best methods of contraception for women with diabetes include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral contraceptives are highly effective in preventing pregnancy and generally safe in women with diabetes (",
"      <a class=\"graphic graphic_table graphicRef69329 \" href=\"mobipreview.htm?19/34/20013\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"       table 3",
"      </a>",
"      ). Estrogen doses of &le;35 mcg have no adverse effects on carbohydrate metabolism, plasma glucose, or insulin sensitivity; estrogen increases HDL and total cholesterol and decreases LDL cholesterol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. On the other hand, progestins increase peripheral insulin resistance, lower HDL cholesterol, and increase LDL cholesterol; the magnitude of these changes depends on the preparation. However, a Cochrane systematic review of studies on the effect of steroid contraceptives on carbohydrate metabolism in women without diabetes concluded no progestin was clearly superior [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/24\">",
"       24",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Other estrogen-progestin preparations (eg, ring, patch) appear to have similar effects, but have not been extensively studied in diabetics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/25\">",
"       25",
"      </a>",
"      ]. The lowest dose of estrogen and progestin should be prescribed to minimize the risk of complications.",
"     </li>",
"     <li>",
"      Depot",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      (DMPA) injections and progestin-only pills are appropriate contraceptive methods in women with no vascular disease. These agents may be slightly safer than combination hormonal contraceptives for diabetic women older than 35 years of age or who smoke or have vascular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/26\">",
"       26",
"      </a>",
"      ], but because long-term use of DMPA induces moderate changes in lipid metabolism that are unfavorable in terms of risk for atherosclerosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/27\">",
"       27",
"      </a>",
"      ], older diabetic women and those with vascular disease should use another method or be carefully monitored for adverse cardiovascular effects (",
"      <a class=\"graphic graphic_table graphicRef69329 \" href=\"mobipreview.htm?19/34/20013\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Intrauterine contraceptive devices (IUD) (eg, copper T380 IUD or a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      -releasing IUD) are as safe and effective as for nondiabetic women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. They are a good alternative for women with microvascular disease who may be at higher risk for cardiovascular complications from oral contraceptives (",
"      <a class=\"graphic graphic_table graphicRef69329 \" href=\"mobipreview.htm?19/34/20013\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74890 \" href=\"mobipreview.htm?12/13/12506\">",
"       table 3",
"      </a>",
"      ). Diabetic women are at increased risk for developing endometrial cancer; use of the high dose levonorgestrel-releasing IUD (52 mg levonorgestrel LNg20) should be protective against development of endometrial hyperplasia (the precursor to endometrial cancer) and may reduce this risk. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=see_link\">",
"       \"Overview of intrauterine contraception\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Barrier methods are effective if used correctly and they do not affect glycemic control. However, these methods are not as reliable as other methods because they are often not used correctly or with each episode of coitus. Fertility-awareness based methods, used alone or in conjunction with barrier methods, are also problematic because diabetic women are more likely to have menstrual irregularities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42487/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/47/15091?source=see_link\">",
"       \"Patient information: Preparing for pregnancy when you have diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prepregnancy planning, good glycemic control, and early identification and treatment of diabetes-related morbidity are essential for optimizing maternal and fetal outcome in women with type 1 and type 2 diabetes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Maternal evaluation and intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A checklist of issues to address during prepregnancy evaluation of women with diabetes mellitus is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef79625 \" href=\"mobipreview.htm?35/33/36380\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Maternal evaluation and intervention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/1\">",
"      Lawrence JM, Contreras R, Chen W, Sacks DA. Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. Diabetes Care 2008; 31:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/2\">",
"      American Diabetes Association. Preconception care of women with diabetes. Diabetes Care 2004; 27 Suppl 1:S76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/3\">",
"      Ray JG, O'Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM 2001; 94:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/4\">",
"      Pearson DW, Kernaghan D, Lee R, et al. The relationship between pre-pregnancy care and early pregnancy loss, major congenital anomaly or perinatal death in type I diabetes mellitus. BJOG 2007; 114:104.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Clinical Excellence (NICE). Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period, 2008, London. Royal College of Obstetricians and Gynaecologists Press.",
"    </li>",
"    <li>",
"     Scottish Intercollegiate Guidelines Network (SIGN). Maintenance of diabetes: a national clinical guideline, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/7\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/8\">",
"      Greene MF, Hare JW, Cloherty JP, et al. First-trimester hemoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy. Teratology 1989; 39:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/9\">",
"      Miller E, Hare JW, Cloherty JP, et al. Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers. N Engl J Med 1981; 304:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/10\">",
"      Ylinen K, Aula P, Stenman UH, et al. Risk of minor and major fetal malformations in diabetics with high haemoglobin A1c values in early pregnancy. Br Med J (Clin Res Ed) 1984; 289:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/11\">",
"      Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care 2007; 30:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/12\">",
"      Holmes VA, Young IS, Patterson CC, et al. Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the diabetes and pre-eclampsia intervention trial. Diabetes Care 2011; 34:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/13\">",
"      Evers IM, de Valk HW, Visser GH. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ 2004; 328:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/14\">",
"      Leipold H, Worda C, Schwindt J, et al. Severe diabetic fetopathy despite strict metabolic control. Wien Klin Wochenschr 2005; 117:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/15\">",
"      Kerssen A, Evers IM, de Valk HW, Visser GH. Poor glucose control in women with type 1 diabetes mellitus and 'safe' hemoglobin A1c values in the first trimester of pregnancy. J Matern Fetal Neonatal Med 2003; 13:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/16\">",
"      Yogev Y, Chen R, Ben-Haroush A, et al. Continuous glucose monitoring for the evaluation of gravid women with type 1 diabetes mellitus. Obstet Gynecol 2003; 101:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/17\">",
"      Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/18\">",
"      Jovanovic-Peterson, L, Peterson, CM. Is pregnancy contraindicated in women with diabetes mellitus?. Diabet Nephrop 1984; 3:36.",
"     </a>",
"    </li>",
"    <li>",
"     www.Reprotox.org. (Accessed on May 06, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/20\">",
"      Bech K, H&oslash;ier-Madsen M, Feldt-Rasmussen U, et al. Thyroid function and autoimmune manifestations in insulin-dependent diabetes mellitus during and after pregnancy. Acta Endocrinol (Copenh) 1991; 124:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/21\">",
"      Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care 2008; 31:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/22\">",
"      Arias, RD, Mestman, JH. Contraception and diabetes. Dialogues in Contraception 2005; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/23\">",
"      Troisi RJ, Cowie CC, Harris MI. Oral contraceptive use and glucose metabolism in a national sample of women in the united states. Am J Obstet Gynecol 2000; 183:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/24\">",
"      Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2012; 4:CD006133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/25\">",
"      Creasy GW, Fisher AC, Hall N, Shangold GA. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile. J Reprod Med 2003; 48:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/26\">",
"      ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/27\">",
"      Kongsayreepong R, Chutivongse S, George P, et al. A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1993; 47:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/28\">",
"      Kimmerle R, Weiss R, Berger M, Kurz KH. Effectiveness, safety, and acceptability of a copper intrauterine device (CU Safe 300) in type I diabetic women. Diabetes Care 1993; 16:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/29\">",
"      Rogovskaya S, Rivera R, Grimes DA, et al. Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial. Obstet Gynecol 2005; 105:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42487/abstract/30\">",
"      Strotmeyer ES, Steenkiste AR, Foley TP Jr, et al. Menstrual cycle differences between women with type 1 diabetes and women without diabetes. Diabetes Care 2003; 26:1016.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4811 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_31_42487=[""].join("\n");
var outline_f41_31_42487=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MATERNAL EVALUATION AND INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2266212\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2266094\">",
"      - Target",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Medications to avoid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2266303\">",
"      - Angiotensin-converting enzyme inhibitors and receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2266311\">",
"      - Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thyroid disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      General issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Folic acid supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4811\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4811|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/27/44477\" title=\"figure 1\">",
"      HbA1c and fetal malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4811|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/33/36380\" title=\"table 1\">",
"      Preconception control in IDDM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/34/20013\" title=\"table 2\">",
"      WHO MEC for patients with endocrine disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/13/12506\" title=\"table 3\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/19/42295?source=related_link\">",
"      Approach to the adult with asymptomatic bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31414?source=related_link\">",
"      Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24985?source=related_link\">",
"      Diabetic autonomic neuropathy of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11993?source=related_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5081?source=related_link\">",
"      Folic acid for prevention of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20794?source=related_link\">",
"      Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/47/15091?source=related_link\">",
"      Patient information: Preparing for pregnancy when you have diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/25/16794?source=related_link\">",
"      Preconception evaluation and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/19/21816?source=related_link\">",
"      Pregnancy in women with diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/27/36281?source=related_link\">",
"      Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9210?source=related_link\">",
"      Screening and diagnosis of diabetes mellitus during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_31_42488="Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma";
var content_f41_31_42488=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/31/42488/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/31/42488/contributors\">",
"     Antonio C Buzaid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/31/42488/contributors\">",
"     Jeffrey E Gershenwald, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/31/42488/contributors\">",
"     Merrick I Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/31/42488/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/31/42488/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/31/42488/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/31/42488/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/31/42488/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to be useful, a staging system must be simple, practical, and accurately reflect the prognosis of the patients to whom it is being applied. Detailed analyses of large databases of patients presenting with newly diagnosed cutaneous melanoma have allowed the correlation of pathologic and clinical parameters with long-term outcome.",
"   </p>",
"   <p>",
"    This information is incorporated into a staging system that was originally developed by the American Joint Committee on Cancer (AJCC) subsequently adopted by the International Union for Cancer Control (UICC). This tumor, node, metastasis (TNM) system relies upon assessments of the primary tumor (T), regional lymph nodes (N), and distant metastatic sites (M). The seventh (2010) edition of this staging system is based upon an analysis of over 38,900 patients with cutaneous melanoma from the AJCC Melanoma Staging Database. The seventh TNM staging system went into effect at the beginning of 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2010 TNM staging system and other prognostic factors for cutaneous melanoma are discussed here. The approach to staging is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35065?source=see_link\">",
"     \"Staging work-up and surveillance after treatment of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS AFFECTING STAGING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Primary tumor (T)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathologic factors incorporated into the 2010 TNM staging system are the thickness of the primary tumor (originally described by Breslow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/3\">",
"     3",
"    </a>",
"    ]), the presence or absence of ulceration of the overlying epithelium, and the mitotic rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The prognostic implications of these parameters were derived from the AJCC Melanoma Staging Database, which included over 27,000 patients who had clinically or pathologically localized melanoma (",
"    <a class=\"graphic graphic_figure graphicRef53002 \" href=\"mobipreview.htm?11/60/12225\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The thickness of the primary tumor (T) defines four categories (",
"    <a class=\"graphic graphic_table graphicRef50225 \" href=\"mobipreview.htm?7/61/8157\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      T1: &le;1.0 mm",
"     </li>",
"     <li>",
"      T2: 1.01 to 2.0 mm",
"     </li>",
"     <li>",
"      T3: 2.01 to 4.0 mm",
"     </li>",
"     <li>",
"      T4: &gt;4.0 mm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The T categories are subdivided into \"a\" or \"b\" based upon the presence or absence of ulceration and the mitotic rate (",
"    <a class=\"graphic graphic_table graphicRef50225 \" href=\"mobipreview.htm?7/61/8157\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Tumor thickness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the AJCC Melanoma Staging Database, increasing tumor thickness correlated with a significantly poorer prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The 10-year survival decreased progressively, from 96 percent with primary lesions &lt;0.5 mm thick to 54 percent with lesions 4.01 to 6.0 mm thick.",
"   </p>",
"   <p>",
"    Evaluation of the entire tumor from an excisional biopsy, rather than a wedge or punch biopsy, is recommended to ensure the measurement of the thickest part of the lesion; a shave biopsy can compromise this evaluation and is therefore discouraged. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\", section on 'Initial biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The maximal tumor thickness is measured at a right angle to the surface of the skin over the tumor mass. The upper reference point is the superficial aspect of the granular cell layer of the epidermis or the base of the lesion if the tumor is ulcerated. The lower reference point is the deepest point of invasion and may be represented by \"detached\" cell clusters beneath the mass. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22009?source=see_link\">",
"     \"Pathologic characteristics of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11493736\">",
"    <span class=\"h4\">",
"     Thin (T1) melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A population-based prospective melanoma registry of 26,736 patients with primary cutaneous melanoma &le;1.00 mm thick analyzed factors associated with prognosis in an effort to identify those patients at increased risk of recurrence and melanoma-related death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall melanoma-specific survival at 20 years was 96 percent. On multivariate analysis, the most important factors associated with survival were tumor thickness (&ge;0.75 mm versus &le;0.25 mm, hazard ratio [HR] 4.3, 95% CI 2.8-6.8) and age at diagnosis (&gt;65 years versus &lt;25 years HR 2.8, 95% CI 1.8-4.5). Of note, the original cutoff described by Breslow (&lt;0.75 versus &gt;0.75 mm) showed a powerful separation in the melanoma-specific survival (",
"    <a class=\"graphic graphic_table graphicRef83111 \" href=\"mobipreview.htm?4/24/4491\">",
"     table 2",
"    </a>",
"    ). Other factors significantly associated with an increased risk of melanoma-associated death location of the primary tumor on the scalp or neck compared with the trunk, acral lentiginous melanoma rather than cutaneous lesions, and nodular melanoma rather than superficial spreading lesions. Importantly, however, ulceration was not included in this large series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mitotic rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mitotic rate was incorporated into the 2010 TNM staging system based upon the observation that it was the second most important prognostic factor in 11,664 patients with localized melanoma analyzed in the AJCC Melanoma Staging Database [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In that series, there was a highly significant correlation between increasing mitotic rate and declining survival rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/5\">",
"     5",
"    </a>",
"    ]. The 10-year survival rate decreased progressively from 93 percent for those with &lt;1",
"    <span class=\"nowrap\">",
"     mitosis/mm",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    to 48 percent for those with &gt;20",
"    <span class=\"nowrap\">",
"     mitoses/mm",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    On multivariate analysis, the mitotic rate was the second most important prognostic factor, behind the thickness of the primary tumor.",
"   </p>",
"   <p>",
"    The mitotic rate should be assessed in all primary melanomas. The recommended approach to determining the mitotic rate is described in detail in the American Joint Committee on Cancer Staging Manual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. In brief, the area of dermis containing the most mitoses (the \"hot spot\") is identified. Once the hot spot is identified, mitoses in adjacent fields within a total area of 1 mm",
"    <sup>",
"     2",
"    </sup>",
"    are counted to determine the mitotic rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17783485\">",
"    <span class=\"h3\">",
"     Ulceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulceration is defined as the absence of an intact epithelium over the melanoma. Ulceration is an important prognostic factor of the primary tumor in the AJCC staging system. Outcomes in patients with ulcerated primary tumors are worse than in patients with primary melanomas of the same thickness but without ulceration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lymphatic involvement (N)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional lymph node spread is a common site of metastatic disease from cutaneous melanoma and has a major negative impact on long-term outcome. The clinical approach to the evaluation and management of regional lymph nodes is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26664?source=see_link\">",
"     \"Evaluation and treatment of regional lymph nodes in melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Node classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;For staging purposes, all patients with histologic confirmation of nodal disease and without distant metastases are classified as stage III regardless of the extent of the nodal tumor burden. In the TNM system, the American Joint Committee on Cancer (AJCC) Melanoma Task Force considers it acceptable to classify node-positive metastases based solely on immunohistochemical staining, even for aggregates of a few cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the analysis of the AJCC Melanoma Staging Database of 3307 patients with stage III melanoma, micrometastases were diagnosed pathologically after sentinel lymph node (SLN) biopsy and completion lymphadenectomy in patients without clinical or imaging evidence of regional disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In contrast, macrometastases were defined as lymph nodes detected clinically or by imaging that were proven to contain tumor histologically by therapeutic lymphadenectomy. There were no specific size criteria associated with the definitions of micrometastasis and macrometastasis.",
"   </p>",
"   <p>",
"    The prognostic data from the AJCC Melanoma Staging Database were used to define the node (N) categories of the 2010 edition of the TNM system (",
"    <a class=\"graphic graphic_table graphicRef50225 \" href=\"mobipreview.htm?7/61/8157\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74483 \" href=\"mobipreview.htm?22/8/22656\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NX - Nodes are not assessable (eg, previously resected for other reasons).",
"     </li>",
"     <li>",
"      N0 - No regional lymphatic metastases.",
"     </li>",
"     <li>",
"      N1 - One involved lymph node. N1 disease is subdivided into N1a (micrometastasis) and N1b (macrometastasis).",
"     </li>",
"     <li>",
"      N2 - N2a and N2b are defined by the presence of two or three involved nodes, with N2a including those with micrometastases and N2b including those with at least one node with a macrometastasis. A separate designation, N2c, is reserved for those without lymph node involvement but with in transit or satellite metastasis.",
"     </li>",
"     <li>",
"      N3 - four or more positive nodes, or matted nodes, or in transit",
"      <span class=\"nowrap\">",
"       metastases/satellites,",
"      </span>",
"      with one or more positive nodes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although all of these patients are classified as stage III, the prognostic implications vary depending upon the extent of the nodal tumor burden and other features of the primary tumor. The AJCC Melanoma Staging Database contained complete clinicopathologic and follow-up data on 2313 patients with stage III melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with nodal disease limited to micrometastases, the most important factor affecting prognosis was the number of nodes involved (five-year survival rates with one, two, or three positive lymph nodes were 71, 65, and 61 percent, respectively). On multivariate analysis, other factors independently affecting prognosis in patients with micrometastases included age and various features of the primary tumor including anatomic site, thickness, ulceration, and mitotic rate.",
"     </li>",
"     <li>",
"      For patients with macrometastases in the regional nodes, the number of nodes was significantly associated with prognosis (five-year survival rates one, two, or three positive lymph nodes were 50, 43, and 40 percent, respectively). The characteristics of the primary tumor were not independently associated with prognosis, unlike patients with disease limited to micrometastases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conditional survival (the survival probability after a given length of survival) is more optimistic and realistic for cancer survivors compared with estimates based exclusively upon the time of original treatment. In a retrospective analysis of 760 patients who underwent lymphadenectomy for node-positive melanoma, conditional disease-specific survival improved from 78 to 90 percent from year 0 to year 5 for patients with stage IIIa melanoma, and from 54 to 79 percent and 39 to 78 percent for those with stage IIIb and IIIc disease (",
"    <a class=\"graphic graphic_table graphicRef50225 \" href=\"mobipreview.htm?7/61/8157\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74203 \" href=\"mobipreview.htm?34/20/35149\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Satellite lesions and in transit metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Satellite lesions are discrete nests of melanoma cells that are clearly separated from the body of the tumor by normal reticular dermal collagen or subcutaneous fat. Such lesions may be detected clinically (macrosatellites) or identified microscopically (microsatellites). Microsatellites are observed in up to one-third of primary melanoma lesions &gt;3 mm thick, compared to less than 5 percent of smaller lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/7\">",
"     7",
"    </a>",
"    ]. In transit metastases include skin or subcutaneous metastases that are more than 2 cm from the primary lesion, but not beyond the regional nodal basin.",
"   </p>",
"   <p>",
"    Satellite lesions and in transit metastases are grouped together and considered intralymphatic in the TNM staging system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the AJCC validation study, these lesions essentially carried the same negative prognostic implications as other lymph node metastases. Satellite lesions and in transit metastases in the absence of concomitant regional nodal disease are classified as N2c, stage IIIB. If satellite lesions and in transit metastases are associated with lymph node involvement, they are classified as N3, stage IIIC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     RT-PCR analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reverse transcriptase polymerase chain reaction (RT-PCR) is a technique that allows detection of submicroscopic levels of tumor-specific genetic material, which cannot be identified by routine hematoxylin and eosin staining or immunohistochemistry.",
"   </p>",
"   <p>",
"    The prognostic significance of a positive RT-PCR assay remains uncertain. RT-PCR should NOT be used in patient management decisions outside of a clinical trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results have been conflicting in studies that evaluated whether the detection of melanoma markers by RT-PCR in histologically negative sentinel lymph nodes is an independent prognostic factor for disease recurrence and overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. The largest of these was a prospective evaluation of 1446 patients enrolled in the Sunbelt Melanoma Trial, all of whom had histologically negative SLNs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/9\">",
"     9",
"    </a>",
"    ]. Tumor markers were detected in the SLN by RT-PCR in 43 percent of patients using a panel of four markers. At a median follow-up of 30 months, SLN RT-PCR positivity was not associated with a significant difference in disease recurrence (11 percent versus 10 percent in those with a negative RT-PCR analysis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Distant metastases (M)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with distant metastases are subclassified according to the site(s) of disease involvement and the serum lactic dehydrogenase (LDH) level (",
"    <a class=\"graphic graphic_figure graphicRef61656 \" href=\"mobipreview.htm?21/27/21950\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      M1a &mdash; Metastases to distant skin, subcutaneous, or lymph node sites, with a normal serum LDH, are associated with the best prognosis and categorized as M1a.",
"     </li>",
"     <li>",
"      M1b &mdash; Lung metastases in patients with a normal serum LDH have a poorer prognosis than skin, subcutaneous, and lymphatic disease but better than metastases to other visceral sites. These patients are categorized as M1b.",
"     </li>",
"     <li>",
"      M1c &mdash; Metastases to other visceral sites with a normal serum LDH OR any metastasis associated with an elevated serum LDH have the worst prognosis, and are classified as M1c disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum LDH is an important, independent prognostic factor in patients with disseminated melanoma. In the 764 patients with distant metastases in the AJCC Melanoma Staging Database, the one- and two-year survival rates were significantly higher for those with a normal serum LDH (65 versus 32 percent and 40 versus 18 percent, respectively, compared to those with an elevated serum LDH).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     STAGE GROUPING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 TNM staging system groups patients into prognostic categories based upon evaluations of the primary tumor (T) and the presence or absence of regional lymphatic (N) and distant metastases (M) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Patients are divided into four stages, which are presented in detail in Table 2 (",
"    <a class=\"graphic graphic_table graphicRef74203 \" href=\"mobipreview.htm?34/20/35149\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Stage I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage I melanoma is limited to patients with low-risk primary melanomas (T1a through T2a), without evidence of regional or distant metastases. Stage I is divided into stages IA and IB, based upon the thickness of the primary tumor, its mitotic rate, and the presence or absence of ulceration. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Primary tumor (T)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Stage II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage II disease includes primary tumors that are at higher risk of recurrence (T2b through T4b), but do not have any evidence of lymphatic disease or distant metastases. Stage II is divided into stage IIA, IIB, and IIC, depending upon tumor thickness and the presence or absence of ulceration. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Primary tumor (T)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Stage III",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage III disease includes those patients with pathologically documented involvement of regional lymph nodes or the presence of in transit or satellite metastases (N1-N3). Patients with stage III disease are subclassified as having stage IIIA, IIIB, or IIIC disease, depending upon the extent of lymphatic disease. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Lymphatic involvement (N)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Stage IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of distant metastases defines stage IV disease (M1a-M1c). There are no subgroups. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Distant metastases (M)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Unknown primary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with isolated metastases identified in lymph nodes, skin, or subcutaneous tissue who do not have an identifiable primary cutaneous melanoma are classified as stage III, assuming no other sites of disease are identified after an appropriate staging evaluation. Other sites of metastases from an unknown primary melanoma are classified as stage IV. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Melanoma with unknown primary'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIFFERENCES FROM 2002 TNM SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key differences between the 2010 TNM staging system and the 2002 staging system include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitotic rate, defined as",
"      <span class=\"nowrap\">",
"       mitoses/mm",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      has been incorporated as a primary prognostic factor in defining the tumor (T) stage. The Clark level of invasion, which was used in conjunction with tumor thickness in the sixth version of the TNM system, is not a statistically significant prognostic factor on multivariate analysis and is no longer utilized.",
"     </li>",
"     <li>",
"      Immunohistochemical detection of melanoma in regional lymph nodes is now acceptable evidence of disease involvement, rather than just hematoxylin and eosin.",
"     </li>",
"     <li>",
"      There is no minimum tumor burden to define positive regional lymph node involvement. Previously tumor deposits &lt;0.2 mm in diameter were not considered clinically significant.",
"     </li>",
"     <li>",
"      Isolated metastases arising in lymph nodes, skin, or subcutaneous tissue, without an identifiable primary, are classified as stage III rather than stage IV.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179248529\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND SURVIVAL: PREDICTION TOOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AJCC database of over 25,000 patients with stage I and II melanoma was used to develop and validate an electronic prediction tool for patients presenting with localized disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/12\">",
"     12",
"    </a>",
"    ]. This tool is available on the internet to assist in assessing risk and decision making (",
"    <a class=\"external\" href=\"file://www.melanomaprognosis.org/\">",
"     www.melanomaprognosis.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OTHER PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other clinical and pathologic parameters have been analyzed for their ability to predict long-term outcome in patients with cutaneous melanoma. Some of these factors are independent predictors of outcome but are not included in the staging system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older patients tend to present with thicker primary tumors, but older age itself appears to have an independent negative effect on survival. In a multivariate analysis of 10,233 cases from the American Joint Committee on Cancer (AJCC) database, age was an independent prognostic factor, even when other variables (thickness of tumor, mitotic rate, presence or absence of ulceration, primary site, and sex) were considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the possibility that the age data may have been confounded by other causes of mortality cannot be excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women are more likely than men to have thin lesions that are not ulcerated and that are located on the extremities, all favorable prognostic factors. Even after allowing for these differences, female gender appears to be associated with a better prognosis for patients with stage I or II melanoma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multivariate analysis of 10,233 patients in the American Joint Committee on Cancer (AJCC) database, female gender was significantly associated with a better prognosis after incorporating data from other prognostic factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an analysis of 2672 patients with stage",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      melanoma enrolled in four adjuvant therapy trials conducted by the EORTC, female gender was associated with significantly better overall survival and disease specific survival (HRs 0.70 and 0.74, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Sunbelt Melanoma Trial, a multivariate analysis of 1829 patients (all of whom had undergone sentinel lymph node biopsy) found that male gender was an independent risk factor for worse overall survival (relative risk [RR] 1.45, 95% CI 1.21 - 1.77) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of gender differences for patients with stage III or stage IV disease are less clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/15-18\">",
"     15-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Anatomic location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous melanomas arising in the head and neck area, trunk, and possibly the lower extremity have a worse prognosis than those arising on the upper extremity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/5,15,19\">",
"     5,15,19",
"    </a>",
"    ]. However, the site of the primary tumor is less important than the factors included in the AJCC staging system (eg, tumor thickness, mitotic rate, ulceration, nodal involvement).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pathologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of pathologic factors that are not included in the AJCC staging system have been studied for their potential effect on prognosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growth pattern &ndash; The four major growth patterns (or histologic subtypes) are lentigo maligna melanoma, nodular melanoma, superficial spreading melanoma, and acral lentiginous melanoma. Although many physicians assumed that patients with nodular melanoma have a worse prognosis than those with superficial spreading tumors, multivariate analyses showed that prognostic differences are accounted for by other factors (tumor thickness, ulceration) that are included in the AJCC staging system [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22009?source=see_link\">",
"       \"Pathologic characteristics of melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lymphatic invasion &ndash; Lymphatic invasion within the tumor has been identified as a negative prognostic factor in a retrospective analysis of 251 patients treated for vertical growth phase melanoma between 1972 and 1991 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/21\">",
"       21",
"      </a>",
"      ]. Patients did not have regional lymph node involvement at presentation and had at least 10 years follow-up. The endpoint was metastasis-free survival at 10 years. Multivariate analysis that included thickness of the primary lesion, mitotic rate, and anatomic site found that lymphatic invasion was a statistically significant independent negative prognostic factor (odds ratio 2.2).",
"     </li>",
"     <li>",
"      Other histopathologic findings &ndash; Other pathologic factors that have been associated with an improved prognosis in some reports include the presence of lymphocyte infiltration in the tumor and histologic evidence of regression in the primary tumor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/20,22-24\">",
"       20,22-24",
"      </a>",
"      ]. However, multivariate analyses of large series have not established a definitive role for these factors.",
"     </li>",
"     <li>",
"      Desmoplastic melanoma &ndash; Desmoplastic melanoma is a rare variant that comprises less than 5 percent of cases. Although desmoplastic melanomas may be locally aggressive, the prognosis appears to be better than with other advanced lesions. Although there may be prognostic differences for patients with desmoplastic melanoma, the same TNM staging system is used in these cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/1\">",
"       1",
"      </a>",
"      ]. The clinical features of desmoplastic melanomas and desmoplastic neurotropic melanomas are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=see_link&amp;anchor=H15#H15\">",
"       \"Initial surgical management of melanoma of the skin and unusual sites\", section on 'Desmoplastic melanoma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although early case reports suggested that melanomas arising during pregnancy were more aggressive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/25\">",
"     25",
"    </a>",
"    ], subsequent series have not documented a negative impact of pregnancy in women with melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/22,26-28\">",
"     22,26-28",
"    </a>",
"    ]. In the largest series, 412 women diagnosed during or within one year after pregnancy were compared to an equal number of nonpregnant women with melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/26\">",
"     26",
"    </a>",
"    ]. Detailed analyses showed that the primary tumors had an almost identical tumor thickness, with no differences in tumor stage or survival between the groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Circulating melanoma cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies and a systematic review of the literature have suggested that detection of melanoma cells in the peripheral blood using RT-PCR for tyrosinase and other markers may identify patients at increased risk for relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/29-34\">",
"     29-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This approach has not been validated for general use, but the presence of circulating tumor cells may eventually be useful in identifying patients at increased risk for relapse. As an example, samples from 320 patients with stage III melanoma were analyzed with a panel of three markers (MART-1, MAGE-A3, GalNAc-T) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/35\">",
"     35",
"    </a>",
"    ]. All patients had undergone a complete lymph node dissection and were enrolled in an adjuvant trial. Patients whose samples were positive for two or more of these biomarkers had a significantly worse distant metastasis free survival and reduced recurrence free survival (hazard ratios 2.1 and 1.7, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Serum S-100 protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;S-100 protein is a dimeric protein whose biologic function is unknown; serum levels are correlated with clinical stage in patients with cutaneous melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/36\">",
"     36",
"    </a>",
"    ]. Levels of S-100 may also be a significant prognostic factor for outcome in patients with resected cutaneous melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/37-40\">",
"     37-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a multivariate analysis of a series of 1007 patients with stage I to III cutaneous melanoma, elevated serum S-100 following resection was associated with decreased likelihood of five year survival in all patients (51 versus 91 percent in those with normal levels) and in those with stage II to III disease (6 versus 30 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/37\">",
"     37",
"    </a>",
"    ]. Elevated serum S-100 protein was an independent predictor of survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Gene expression profiling and proteomics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of gene and protein expression in tissues, serum, and other biologic samples (gene expression profiling and proteomics) should provide an improved understanding of the molecular complexities in melanoma. New techniques can rapidly analyze large numbers of targets from many samples and may identify unique prognostic indicators in patients with melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     MELANOMA WITH UNKNOWN PRIMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional patients present with metastatic melanoma involving lymph nodes, cutaneous, or visceral sites. In a single institution experience of 2485 melanoma patients, a primary tumor could not be identified in 65 (2.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients who present with lymph node metastases only have a survival similar (or slightly better) compared to those with lymph node metastases and a known primary and should be treated as if they had stage III disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. Patients who present with widely metastatic disease have a survival that is similar to or slightly better those with a known primary site, particularly if such an analysis incorporates other prognostic characteristics such as stage or number of metastatic sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A detailed history and physical examination to search for a potential primary, with a focus on the surround skin in patients presenting with nodal or soft tissue disease, is indicated for patients presenting with melanoma from an unknown primary. A detailed search for an occult mucosal or ocular primary melanoma is generally not indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42488/abstract/51\">",
"     51",
"    </a>",
"    ]. Data on molecular characterization of tumors from an unknown primary suggest a profile that mirrors that of cutaneous tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/34/1576?source=see_link&amp;anchor=H220084#H220084\">",
"     \"The molecular biology of melanoma\", section on 'Genetic abnormalities in melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The TNM staging of patients presenting with melanoma of an unknown primary is discussed above. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Unknown primary'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A simple, accurate staging and prognostic system provides important insight into the prognosis of patients with cutaneous melanoma, thus facilitating appropriate treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Staging and prognosis are based upon the tumor (T) node (N) metastasis (M) system, which incorporates information about the primary tumor, regional lymphatics, and potential distant metastatic sites. The American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) revised this staging system in 2009 into the seventh TNM system, which is the standard staging system for patients with cutaneous melanoma (",
"      <a class=\"graphic graphic_table graphicRef50225 \" href=\"mobipreview.htm?7/61/8157\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74203 \" href=\"mobipreview.htm?34/20/35149\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognostic factors affecting staging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Stage grouping'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/1\">",
"      Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199.",
"     </a>",
"    </li>",
"    <li>",
"     Melanoma of the Skin. In: American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.325.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/3\">",
"      Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/4\">",
"      Green AC, Baade P, Coory M, et al. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol 2012; 30:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/5\">",
"      Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 2011; 29:2199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/6\">",
"      Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010; 28:2452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/7\">",
"      Le&oacute;n P, Daly JM, Synnestvedt M, et al. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 1991; 126:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/8\">",
"      Mocellin S, Hoon DS, Pilati P, et al. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis. J Clin Oncol 2007; 25:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/9\">",
"      Scoggins CR, Ross MI, Reintgen DS, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 2006; 24:2849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/10\">",
"      Kammula US, Ghossein R, Bhattacharya S, Coit DG. Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction--staged sentinel lymph nodes from melanoma patients. J Clin Oncol 2004; 22:3989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/11\">",
"      Takeuchi H, Morton DL, Kuo C, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 2004; 22:2671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/12\">",
"      Soong SJ, Ding S, Coit D, et al. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol 2010; 17:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/13\">",
"      Joosse A, Collette S, Suciu S, et al. Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J Clin Oncol 2012; 30:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/14\">",
"      Scoggins CR, Ross MI, Reintgen DS, et al. Gender-related differences in outcome for melanoma patients. Ann Surg 2006; 243:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/15\">",
"      Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/16\">",
"      Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/17\">",
"      Unger JM, Flaherty LE, Liu PY, et al. Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. Cancer 2001; 91:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/18\">",
"      van der Ploeg AP, van Akkooi AC, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol 2011; 29:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/19\">",
"      Callender GG, Egger ME, Burton AL, et al. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker. Am J Surg 2011; 202:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/20\">",
"      Berwick M, Armstrong BK, Ben-Porat L, et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst 2005; 97:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/21\">",
"      Xu X, Chen L, Guerry D, et al. Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma. Clin Cancer Res 2012; 18:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/22\">",
"      Stensheim H, M&oslash;ller B, van Dijk T, Foss&aring; SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol 2009; 27:45.",
"     </a>",
"    </li>",
"    <li>",
"     Balch CM, Soong SJ, Shaw H, et al. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Cutaneous Melanoma, Balch CM, Houghton A, Milton G, et al (Eds), JB Lippincott, Philadelphia 1991. p.165.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/24\">",
"      Clark WH Jr, Elder DE, Guerry D 4th, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/25\">",
"      PACK GT, SCHARNAGEL IM. The prognosis for malignant melanoma in the pregnant woman. Cancer 1951; 4:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/26\">",
"      O'Meara AT, Cress R, Xing G, et al. Malignant melanoma in pregnancy. A population-based evaluation. Cancer 2005; 103:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/27\">",
"      Daryanani D, Plukker JT, De Hullu JA, et al. Pregnancy and early-stage melanoma. Cancer 2003; 97:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/28\">",
"      Lens MB, Rosdahl I, Ahlbom A, et al. Effect of pregnancy on survival in women with cutaneous malignant melanoma. J Clin Oncol 2004; 22:4369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/29\">",
"      Curry BJ, Myers K, Hersey P. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 1998; 16:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/30\">",
"      Gogas H, Kefala G, Bafaloukos D, et al. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br J Cancer 2002; 87:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/31\">",
"      Voit C, Kron M, Rademaker J, et al. Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J Clin Oncol 2005; 23:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/32\">",
"      Koyanagi K, O'Day SJ, Gonzalez R, et al. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol 2005; 23:8057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/33\">",
"      Mocellin S, Hoon D, Ambrosi A, et al. The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res 2006; 12:4605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/34\">",
"      Fusi A, Collette S, Busse A, et al. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur J Cancer 2009; 45:3189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/35\">",
"      Hoshimoto S, Shingai T, Morton DL, et al. Association Between Circulating Tumor Cells and Prognosis in Patients With Stage III Melanoma With Sentinel Lymph Node Metastasis in a Phase III International Multicenter Trial. J Clin Oncol.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/36\">",
"      Abraha HD, Fuller LC, Du Vivier AW, et al. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol 1997; 137:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/37\">",
"      M&aring;rtenson ED, Hansson LO, Nilsson B, et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol 2001; 19:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/38\">",
"      Domingo-Dom&egrave;nech J, Molina R, Castel T, et al. Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon--comparison with tyrosinase rt-PCR. Oncology 2005; 68:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/39\">",
"      Tarhini AA, Stuckert J, Lee S, et al. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 2009; 27:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/40\">",
"      Aukema TS, Olmos RA, Korse CM, et al. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up. Ann Surg Oncol 2010; 17:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/41\">",
"      Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 2005; 102:6092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/42\">",
"      Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006; 98:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/43\">",
"      Katz KA, Jonasch E, Hodi FS, et al. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res 2005; 15:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/44\">",
"      Schlagenhauff B, Stroebel W, Ellwanger U, et al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer 1997; 80:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/45\">",
"      Anbari KK, Schuchter LM, Bucky LP, et al. Melanoma of unknown primary site: presentation, treatment, and prognosis--a single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer 1997; 79:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/46\">",
"      Cormier JN, Xing Y, Feng L, et al. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 2006; 106:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/47\">",
"      Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 2008; 26:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/48\">",
"      Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/49\">",
"      Vijuk G, Coates AS. Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study. Ann Oncol 1998; 9:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/50\">",
"      Lee CC, Faries MB, Wanek LA, Morton DL. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 2009; 27:3489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42488/abstract/51\">",
"      Ohkawa K, Abe T, Hatano T, et al. The facilitated effect of retinol on rat hepatocarcinogenesis induced by 3'-methyl-4-dimethylaminoazobenzene. Carcinogenesis 1991; 12:2357.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7618 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-6BC967DE50-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_31_42488=[""].join("\n");
var outline_f41_31_42488=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSTIC FACTORS AFFECTING STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Primary tumor (T)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Tumor thickness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11493736\">",
"      Thin (T1) melanoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mitotic rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17783485\">",
"      - Ulceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lymphatic involvement (N)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Node classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Satellite lesions and in transit metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - RT-PCR analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Distant metastases (M)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      STAGE GROUPING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Stage I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Stage II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Stage III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Stage IV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Unknown primary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIFFERENCES FROM 2002 TNM SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179248529\">",
"      PROGNOSIS AND SURVIVAL: PREDICTION TOOL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OTHER PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Anatomic location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pathologic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Circulating melanoma cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Serum S-100 protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Gene expression profiling and proteomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      MELANOMA WITH UNKNOWN PRIMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7618\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7618|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/60/12225\" title=\"figure 1\">",
"      Melanoma - Impact of T stage on prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/8/22656\" title=\"figure 2\">",
"      Melanoma - Impact of lymph node involvement on prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/27/21950\" title=\"figure 3\">",
"      Melanoma - Impact of distant metastases on prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7618|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/61/8157\" title=\"table 1\">",
"      Melanoma 7th TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/24/4491\" title=\"table 2\">",
"      Thickness versus survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/20/35149\" title=\"table 3\">",
"      Melanoma 7th TNM stage group",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26664?source=related_link\">",
"      Evaluation and treatment of regional lymph nodes in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22009?source=related_link\">",
"      Pathologic characteristics of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35065?source=related_link\">",
"      Staging work-up and surveillance after treatment of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/34/1576?source=related_link\">",
"      The molecular biology of melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_31_42489="Prevention of Haemophilus influenzae infection";
var content_f41_31_42489=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of Haemophilus influenzae infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/31/42489/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/31/42489/contributors\">",
"     Sylvia Yeh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/31/42489/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/31/42489/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/31/42489/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/31/42489/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/31/42489/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    serotype b (Hib) was once the most common cause of bacterial meningitis and a frequent cause of other serious bacteremic infections, particularly in early childhood. The widespread use of Hib conjugate vaccines in infancy has led to a dramatic decline in the incidence of invasive Hib disease in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the disease remains common in countries not using the vaccine. Other strains of",
"    <em>",
"     H. influenzae",
"    </em>",
"    , particularly nontypeable",
"    <em>",
"     H. influenzae",
"    </em>",
"    (NTHi), remain important pathogens, causing mucosal and respiratory infections throughout life.",
"   </p>",
"   <p>",
"    Active immunization of young infants is the most important means for prevention of Hib infection. Another means of prevention that is now less commonly used is chemoprophylaxis for susceptible contacts of patients with invasive Hib disease. Passive prophylaxis with hyperimmune globulin is no longer used, except when intravenous immune globulin (IVIG) is administered to immunocompromised individuals who have impaired responses to vaccine (eg, for agammaglobulinemia). The development of vaccines for NTHi remains an active area of research.",
"   </p>",
"   <p>",
"    Prevention of Hib infections will be discussed below. The microbiology and epidemiology are discussed separately, as are the clinical manifestations and treatment of disease (eg, meningitis, epiglottitis, otitis media, sinusitis) (see individual topic reviews). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41608?source=see_link\">",
"     \"Microbiology, epidemiology and treatment of Haemophilus influenzae\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMMUNIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active immunization is the most important means of prevention of",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b (Hib) infection, and it has nearly eliminated disease in most countries where it is used. Type b polysaccharide and polysaccharide conjugate vaccines induce antibodies to the type b capsular polysaccharide (polyribosylribitol phosphate, PRP), which is the most important antigen in conferring protective immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/2\">",
"     2",
"    </a>",
"    ]. Antibodies against PRP activate complement, are opsonophagocytic, bactericidal, and protect animals from lethal Hib challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. In addition, the observed age-related acquisition of natural immunity is associated with lower risk of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Several trials of vaccine-induced immunity, detailed below, have shown dramatic protection.",
"   </p>",
"   <p>",
"    The first vaccine developed for the prevention of invasive Hib was a purified Hib capsular polysaccharide vaccine (PRP). It was licensed in 1985 for use as a single injection in children 18 months of age or older. Polysaccharide vaccines are poorly immunogenic in young children, particularly those younger than 18 months, because of the polysaccharide's inability to induce T-cell-dependent memory. A clinical trial of this vaccine in Finland suggested that a single dose given to children 18 to 71 months of age had protective efficacy of 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Reanalysis of data after several reports of vaccine failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/14\">",
"     14",
"    </a>",
"    ] indicated that the efficacy in children 18 to 36 months of age was incomplete and ranged from 7 to 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/15\">",
"     15",
"    </a>",
"    ]. For a brief time, this vaccine was recommended for toddlers to prevent a proportion of the disease burden in older children, but effectiveness was limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The limited immunogenicity of PRP in young children has been overcome by conjugating the polysaccharide to a carrier protein, thereby inducing a stronger T-cell response. With conjugate vaccines, protective levels of antibodies are achieved after two or three doses in young infants (the number of doses required is dependent on the conjugate carrier). However, because of waning immunity, or an incomplete maturation of antibody by memory B cells, a booster dose is needed between 12 to 18 months to maximize protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Conjugate vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several Hib conjugate vaccines are licensed in the United States and recommended by Advisory Committee on Immunization Practices (ACIP) (",
"    <a class=\"graphic graphic_table graphicRef64312 \" href=\"mobipreview.htm?29/19/30012\">",
"     table 1",
"    </a>",
"    ). After one or more doses, each of these vaccines induces protective levels of antibody in immunocompetent children and adults. These vaccines are also immunogenic in infants but, as described below, the number of doses required varies, as does the amount of antibody induced by each vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       PRP-OMP",
"      </strong>",
"      &ndash; PRP-outer membrane protein conjugate vaccine (PRP-OMP, PedvaxHIB) conjugates PRP to protein components of outer membrane vesicles of a strain of serogroup B",
"      <em>",
"       Neisseria",
"      </em>",
"      meningitis (",
"      <a class=\"graphic graphic_table graphicRef64312 \" href=\"mobipreview.htm?29/19/30012\">",
"       table 1",
"      </a>",
"      ). It is intended to prevent Hib, not",
"      <em>",
"       N. meningitidis",
"      </em>",
"      .",
"      <br/>",
"      <br/>",
"      PRP-OMP induces high antibody responses after a single dose in young infants (around two months of age) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/20-25\">",
"       20-25",
"      </a>",
"      ]. After two doses (given at two and four months of age), more than 94 percent of infants mount an adequate antibody response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/23,26\">",
"       23,26",
"      </a>",
"      ]. Interestingly, a third dose at six months of age does not elicit an additional booster response. For high-risk infants, such as American",
"      <span class=\"nowrap\">",
"       Indian/Alaskan",
"      </span>",
"      Native children, PRP-OMP has been recommended for the first dose in the Hib conjugate vaccine series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      PRP-OMP is licensed in the United States for use in a two-dose primary series (at two and four months) and as a booster dose (at 12 to 15 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27\">",
"       27",
"      </a>",
"      ]. It is also available in a combination with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/17/15639?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      <span class=\"nowrap\">",
"       (PRP-OMP/hepatitis",
"      </span>",
"      B, Comvax).",
"     </li>",
"     <li>",
"      <strong>",
"       PRP-T",
"      </strong>",
"      &ndash; PRP-tetanus toxoid conjugate vaccine (PRP-T) conjugates PRP to tetanus toxoid. Two PRP-T conjugate vaccines are licensed in the United States: ActHIB and Hiberix [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       ActHIB",
"      </strong>",
"      &ndash; ActHIB is licensed in the United States for use in a three-dose primary series (at two, four, and six months) and as a booster dose at 12 to 15 months (",
"      <a class=\"graphic graphic_table graphicRef64312 \" href=\"mobipreview.htm?29/19/30012\">",
"       table 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      ActHIB is available in a combination with diphtheria-tetanus-acellular pertussis vaccine (DTaP) and the inactivated poliovirus (IPV) vaccine",
"      <span class=\"nowrap\">",
"       (DTaP-IPV/Hib,",
"      </span>",
"      Pentacel) for use at 2, 4, 6, and 15 through 18 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/30\">",
"       30",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although whole-cell pertussis vaccine (DTP) is no longer used in the United States, in other countries, PRP-T is reconstituted with whole-cell DTP vaccine and used for the primary series and booster dose. This DTP-Hib vaccine retains immunogenicity for each of the four components and is used in many developing countries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Hiberix",
"      </strong>",
"      &ndash; Hiberix is licensed in the United States for use as the booster dose in children aged 15 months through 4 years who have received a primary Hib vaccination series of two or three doses (depending upon the formulation) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/29\">",
"       29",
"      </a>",
"      ]. It is not licensed for the primary series.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a combination conjugate vaccine against Hib and meningococcus serogroups C and Y (HibMenCY, MenHibrix) was approved in June 2012 for infants and children 6 weeks to 18 months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In prelicensure trials involving approximately 8000 children, HibMenCY vaccine was safe, immunogenic, and did not interfere with immune responses to routine immunizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]. In January 2013, the CDC&rsquo;s ACIP recommended immunization with HibMenCY for infants at increased risk of meningococcal disease (ie, those with persistent complement pathway deficiencies or anatomic or functional asplenia [including sickle cell disease]) and for infants in communities with outbreaks of serogroup C or Y meningococcal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/39\">",
"     39",
"    </a>",
"    ]. The routine and catch-up schedules for HibMenCY are discussed below. (See",
"    <a class=\"local\" href=\"#H86826243\">",
"     'Combination Hib-meningococcal vaccine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hib conjugate vaccine dose and route",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each dose of Hib conjugate vaccine consists of 0.5 mL and is administered intramuscularly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hib conjugate vaccine schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the primary series of Hib conjugate vaccine, which is administered before seven months of age, requires two or three doses, depending upon the vaccine preparation (",
"    <a class=\"graphic graphic_table graphicRef77170 \" href=\"mobipreview.htm?5/59/6077\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27\">",
"     27",
"    </a>",
"    ]. The minimum age for the first dose is six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/40\">",
"     40",
"    </a>",
"    ]. Hib conjugate vaccines (including HibMenCY) can be administered at the same visit as other routine childhood immunizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/39,41,42\">",
"     39,41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link&amp;anchor=H2#H2\">",
"     \"Standard immunizations for children and adolescents\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is ideal to use the same Hib conjugate vaccine to complete the primary series. However, if it is unknown which vaccine was previously administered, or if the same vaccine is not available, the vaccines can be interchanged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27\">",
"     27",
"    </a>",
"    ]. If two different preparations are used, a three-dose primary series is required.",
"   </p>",
"   <p>",
"    In the United States, a booster dose is recommended at 12 to 15 months of age (or as soon thereafter as possible); 12 months is the minimum age for the final dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/40\">",
"     40",
"    </a>",
"    ]. Any of the Hib conjugate vaccines may be used for the booster dose (",
"    <a class=\"graphic graphic_table graphicRef77170 \" href=\"mobipreview.htm?5/59/6077\">",
"     table 2",
"    </a>",
"    ); the vaccine need not be the same as the one used for the primary series.",
"   </p>",
"   <p>",
"    The Hib conjugate vaccine schedule varies from country to country [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/43\">",
"     43",
"    </a>",
"    ]. Some countries do not administer a booster dose after 12 months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Efficacy/effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prelicensure clinical studies of Hib conjugate vaccines in large numbers of infants demonstrated a protective efficacy of &ge;95 percent against invasive Hib disease after completion of the two- or three-dose primary series as recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After licensure, the public health benefit of routine Hib immunization has far exceeded what would have been expected based on the efficacy trials alone. The added benefit appears to be due to herd immunity, such that widespread immunization reduces carriage and transmission in the community, even to those not fully immunized.",
"   </p>",
"   <p>",
"    Invasive Hib disease has been virtually eliminated from the United States and many other countries where the use of Hib conjugate vaccine is routine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. However, because Hib conjugate vaccines are infrequently used in developing countries, the global burden of Hib remains substantial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The World Health Organization estimates that only 42 percent of the eligible population is vaccinated against Hib in developing countries, and only 8 percent in the poorest countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United Kingdom, where from 1992 to 2002, Hib conjugate vaccination was routine at two, three, and four months of age, an increase in Hib disease was noted beginning in 1998, and researchers found that Hib carriage was common in school-age children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/52\">",
"     52",
"    </a>",
"    ]. They postulated that the lack of a booster vaccination may in part have contributed to continued circulation of Hib. In 2003, a booster campaign for children under four years of age was initiated, with a resultant decrease in Hib disease rates.",
"   </p>",
"   <p>",
"    Possibly related to the United States Hib shortage from 2007 to 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/53,54\">",
"     53,54",
"    </a>",
"    ], five cases of invasive Hib disease occurred in children younger than five years in Minnesota during 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/55\">",
"     55",
"    </a>",
"    ]. Of the five children, three were completely unvaccinated due to parental or guardian deferral or refusal, one child was five months of age and had received two doses of PRP-T at two and four months of age, and one child was 15 months of age and had received PRP-OMP at two and four months of age but not the booster dose, based on the recommendations following the announcement of the Hib conjugate vaccine shortage in December 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/53\">",
"     53",
"    </a>",
"    ]. The 15-month-old infant was later diagnosed with hypogammaglobulinemia. Review of Hib conjugate immunization uptake in Minnesota revealed a much lower rate of Hib vaccination coverage following the vaccine shortage announcement compared with previous years, as well as compared with concurrent DTaP and pneumococcal conjugate vaccine coverage.",
"   </p>",
"   <p>",
"    The increased number of cases may reflect increasing carriage and transmission of Hib affecting unvaccinated children during a period of diminished Hib vaccination coverage and prolonged deferral of the booster dose, related to a vaccine shortage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/55\">",
"     55",
"    </a>",
"    ]. Consequently, the longevity of the successful impact of Hib vaccination may be limited when there is a disruption in vaccination supply and delivery. For primary care providers, an effort to maximize delivery of the complete primary series of Hib vaccines in infants is crucial and to ensure an adequate stock of Hib conjugate vaccine for each child being vaccinated in their setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Contraindications and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACIP has identified no contraindications or precautions regarding the administration of Hib conjugate vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic reactions (eg, fever, irritability) are infrequent after Hib immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/57\">",
"     57",
"    </a>",
"    ]. Local reactions, consisting of pain, redness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    swelling at the injection site occur in approximately 25 percent of recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/57\">",
"     57",
"    </a>",
"    ]. Such local reactions usually are mild and resolve within 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Special uses",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Catch-up schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catch-up schedule for Hib conjugate vaccine in immune competent children depends upon the age at which the series is initiated and the number of doses previously received (",
"    <a class=\"graphic graphic_table graphicRef77170 \" href=\"mobipreview.htm?5/59/6077\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/40,42\">",
"     40,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children who are 7 to 11 months of age at initiation of vaccination should receive two doses of Hib conjugate vaccine at four- to eight-week intervals and a booster dose at 12 to 15 months of age, preferably eight weeks after the second dose of the primary series; any vaccine preparation may be used.",
"     </li>",
"     <li>",
"      Children who have received &le;1 dose of Hib conjugate vaccine before one year of age and are now 12 to 15 months of age should receive two doses of Hib conjugate vaccine eight weeks apart.",
"     </li>",
"     <li>",
"      Children with an incomplete series of Hib conjugate vaccination who are now 15 to 59 months of age should receive a single dose of Hib conjugate vaccine.",
"     </li>",
"     <li>",
"      Children &ge;12 months who are at increased risk for meningococcal disease and have not received any doses of Hib or meningococcal vaccine may receive either 1) two doses of HibMenCY, given at least eight weeks apart or 2) a single dose of Hib conjugate vaccine (other than HibMenCY) and two doses of quadrivalent meningococcal conjugate vaccine, given at least 12 weeks apart (if they are &lt;24 months) or eight weeks apart (if they are &ge;24 months). Additional caveats apply if the child has anatomic or functional asplenia and has not completed immunization with the pneumococcal conjugate vaccine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link&amp;anchor=H182642754#H182642754\">",
"       \"Meningococcal vaccines\", section on 'In infants and toddlers'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Impaired host defense",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain individuals may be at increased risk of invasive Hib disease because of immune deficiency or other host-defense abnormalities (eg, sickle cell disease, functional or anatomic asplenia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27\">",
"     27",
"    </a>",
"    ]. These individuals should receive Hib conjugate vaccine 0.5 mL intramuscularly as recommended for all infants. The combination Hib-meningococcal serogroups C and Y conjugate vaccine (HibMenCY) may be used for children 6 weeks through 18 months who are also at risk for meningococcal disease (ie, those with persistent complement pathway deficiencies or anatomic or functional asplenia [including sickle cell disease]).",
"   </p>",
"   <p>",
"    For incompletely immunized children 12 to 59 months of age who are at increased risk of invasive Hib disease, the following is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those who received &le;1 dose of Hib conjugate vaccine before 12 months of age should receive two doses, separated by eight weeks.",
"     </li>",
"     <li>",
"      Those who received two doses of Hib conjugate vaccine before 12 months of age should receive one additional dose (at least two months after the most recent dose).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For unimmunized individuals at increased risk of Hib disease who are older than 59 months, the following is recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those who have sickle cell disease, anatomic or functional asplenia, human immunodeficiency virus, or leukemia should receive a single dose of Hib conjugate vaccine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/58-60\">",
"       58-60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Those who are scheduled for splenectomy should receive a single dose of Hib conjugate vaccine at least two weeks before the procedure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=see_link&amp;anchor=H5#H5\">",
"       \"Prevention of sepsis in the asplenic patient\", section on 'Timing of immunizations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Previous history of invasive Hib disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have invasive Hib infection before 24 months can remain at risk of developing a second episode of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27,61\">",
"     27,61",
"    </a>",
"    ]. Such children should be immunized according to the age-appropriate schedule for unimmunized children and as if they had never received prior Hib vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27\">",
"     27",
"    </a>",
"    ]. Immunization should be initiated one month after the onset of invasive disease, or as soon thereafter as possible.",
"   </p>",
"   <p>",
"    Children who have invasive Hib disease after 24 months of age virtually always develop a protective immune response and do not require immunization.",
"   </p>",
"   <p>",
"    Children who develop invasive Hib disease despite two to three doses of Hib conjugate vaccine and those who have recurrent invasive Hib disease should undergo immunologic evaluation, particularly for IgG2 subclass deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27,62\">",
"     27,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13258?source=see_link&amp;anchor=H7#H7\">",
"     \"IgG subclass deficiency\", section on 'IgG2 deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86826243\">",
"    <span class=\"h3\">",
"     Combination Hib-meningococcal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACIP recommends the HibMenCY vaccine for infants in the United States at increased risk of meningococcal disease (ie, those with persistent complement pathway deficiencies or anatomic or functional asplenia [including sickle cell disease]). HibMenCY is given at 2, 4, 6, and 12 to 15 months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/39,42\">",
"     39,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If an infant at increased risk for meningococcal disease is behind on Hib vaccines, HibMenCY may be used following the same catch-up schedule used for Hib vaccine (",
"    <a class=\"graphic graphic_table graphicRef77170 \" href=\"mobipreview.htm?5/59/6077\">",
"     table 2",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Catch-up schedule'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/39\">",
"     39",
"    </a>",
"    ]. It is particularly important for such children who receive the first dose of HibMenCY at or after 12 months of age to receive two doses, at least 8 weeks apart to ensure protection against serogroups C and Y meningococcal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants and children who receive HibMenCY are not protected against meningococcal serogroups A and W135. Such children who are planning to travel to areas with high endemic rates of meningococcal disease should receive an age-appropriate quadrivalent meningococcal conjugate (MCV4) vaccine at least two weeks before departure to provide protection against serogroups A and W135. Similarly, any child who has not received meningococcal vaccination should receive an age-appropriate series of MCV4 before travel to areas with high endemic rates of meningococcal disease. The appropriate vaccine and number of doses depends upon the underlying condition (",
"    <a class=\"graphic graphic_table graphicRef71265 \" href=\"mobipreview.htm?9/48/9999\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link&amp;anchor=H182642754#H182642754\">",
"     \"Meningococcal vaccines\", section on 'In infants and toddlers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INFECTION CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with known or suspected",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b (Hib) infections should be in private rooms, and hospital personnel should wear a face mask when they are within 3 feet (1 meter) of the patient (ie, droplet precautions) for 24 hours after the initiation of parenteral antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27\">",
"     27",
"    </a>",
"    ]. The doors of rooms used to house these patients may remain open. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link&amp;anchor=H12#H12\">",
"     \"General principles of infection control\", section on 'Droplet precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC PROPHYLAXIS OF CLOSE CONTACTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before the routine use of",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b (Hib) vaccines, a prospective study evaluated 4311 household contacts of 1147 patients with Hib meningitis for the development of invasive Hib disease within 30 days of the onset of illness in the index patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/64\">",
"     64",
"    </a>",
"    ]. The risk of Hib meningitis among household contacts was 585 times the age-adjusted risk in the general population. The overall risk of invasive Hib disease among household contacts was 0. 21 percent; however, the risk varied according to age as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 to 11 months &ndash; 6 percent",
"     </li>",
"     <li>",
"      12 to 23 months &ndash; 1.4 percent",
"     </li>",
"     <li>",
"      24 to 47 months &ndash; 1.5 percent",
"     </li>",
"     <li>",
"      48 to 71 months &ndash; 0.1 percent",
"     </li>",
"     <li>",
"      &ge;6 years &ndash; 0 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If close contacts of the index case receive antimicrobial prophylaxis soon after the index case is diagnosed, pharyngeal carriage of Hib in the contact can be eradicated, thereby reducing the risk of developing invasive disease, and interrupting transmission. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/41/38549?source=see_link\">",
"     \"Pathogenesis and pathophysiology of bacterial meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In placebo-controlled randomized trials and observational studies, administration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose) eliminated oropharyngeal carriage of Hib in at least 95 percent of household or daycare contacts of patients with invasive Hib disease (compared with less than 30 percent of patients in the placebo arm or no treatment arm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/65-69\">",
"     65-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drugs other than",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    that may be used to treat Hib infections, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/70-72\">",
"     70-72",
"    </a>",
"    ],",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/22/12644?source=see_link\">",
"     cefaclor",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/73,74\">",
"     73,74",
"    </a>",
"    ],",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/75\">",
"     75",
"    </a>",
"    ], and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/49/11031?source=see_link\">",
"     erythromycin-sulfisoxazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/73\">",
"     73",
"    </a>",
"    ] are not effective for chemoprophylaxis because they do not reliably eradicate Hib from the nasopharynx. We recommend not using these agents for antimicrobial prophylaxis against invasive Hib disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemoprophylaxis may be indicated for household (or close) contacts of a child with invasive Hib disease, child-care or preschool contacts, and the index patient, depending upon individual circumstances as described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemoprophylaxis is not indicated for contacts of people with invasive disease caused by nontype b strains of",
"    <em>",
"     H. influenzae",
"    </em>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Close contact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Close (household) contact is defined as a person who resides with the index patient or who spent &ge;4 hours with the index patient for at least five of the seven days before the day of hospital admission of the index case [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemoprophylaxis is recommended for all household contacts (including the index case) in the following circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Household with at least one contact &lt;4 years who has not received an age-appropriate number of doses of Hib conjugate vaccine. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hib conjugate vaccine schedules'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The susceptible child(ren) should receive a dose of Hib conjugate vaccine and be scheduled for completion of Hib immunization if additional doses are necessary to complete immunization. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hib conjugate vaccine schedules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Household with a contact who is an immunocompromised child, regardless of that child's Hib immunization status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69447014\">",
"    <span class=\"h4\">",
"     Monitoring for illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to receiving antimicrobial prophylaxis, exposed unimmunized or incompletely immunized children who are household contacts of patients with invasive Hib disease must be carefully observed for signs of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27\">",
"     27",
"    </a>",
"    ]. Exposed children in whom febrile illness develops should receive prompt medical attention.",
"    <br/>",
"    <br/>",
"    The child should be examined carefully for a focus of infection, including consideration of a lumbar puncture based on clinical presentation and risk factors, such as the age of the patient. If a focus of infection is found, the infection should be treated accordingly after appropriate cultures are obtained. If occult bacteremia is suspected, parenteral antibiotics should be administered pending the culture result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Child care or preschool contacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemoprophylaxis for child care or school contacts after one case of invasive Hib disease is controversial. Epidemiologic studies have reached different conclusions regarding the risk among child care contacts compared with household contacts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics recommends chemoprophylaxis for child-care and preschool contacts when unimmunized or incompletely immunized children attend the facility and two or more cases of Hib invasive disease have occurred among attendees within 60 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposed unimmunized or incompletely immunized children who are child-care or preschool contacts of patients with invasive Hib disease must be carefully observed for signs of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27\">",
"     27",
"    </a>",
"    ]. Exposed children in whom febrile illness develops should receive prompt medical attention, as described above. (See",
"    <a class=\"local\" href=\"#H69447014\">",
"     'Monitoring for illness'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Index patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the index patient was treated with an agent other than",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , antimicrobial therapy to eradicate nasopharyngeal carriage is recommended if either of the following also is true for the index patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27,77-79\">",
"     27,77-79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is younger than two years of age,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Lives in a household with a child &lt;4 years of age who has not received an age-appropriate number of doses of Hib conjugate vaccine, or an immunocompromised child. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hib conjugate vaccine schedules'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Recommended regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylaxis should be initiated as soon as possible in contacts; in the index case, it should be initiated within two weeks of the onset of disease and may be initiated in conjunction with treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     Rifampin",
"    </a>",
"    is the drug of choice for chemoprophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27\">",
"     27",
"    </a>",
"    ]. The regimen is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"       Rifampin",
"      </a>",
"      20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum dose 600 mg) once per day for four days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    for infants &lt;1 month of age has not been established; some experts recommend lowering the dose to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consultation with an expert in infectious diseases is recommended for contacts in whom",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    is contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PASSIVE IMMUNIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A human hyperimmunoglobulin from immunized adult donors (bacterial polysaccharide immunoglobulin) was developed before",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b (Hib) conjugate vaccines were widely available. Although this preparation was effective in preventing disease in high-risk settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/81\">",
"     81",
"    </a>",
"    ], it is no longer available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     NONTYPEABLE H. INFLUENZAE (NTHi) VACCINE CANDIDATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the routine use of type b vaccines has virtually eliminated invasive",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b (Hib) disease, the burden of disease caused by other serotypes and NTHi remains unchanged. NTHi are important pathogens as a cause of acute otitis media, acute sinusitis, bronchitis, and community-acquired pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41608?source=see_link\">",
"     \"Microbiology, epidemiology and treatment of Haemophilus influenzae\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/55/2938?source=see_link&amp;anchor=H19#H19\">",
"     \"Epidemiology, pathogenesis, and etiology of pneumonia in children\", section on 'In children &lt;5 years'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=see_link&amp;anchor=H17#H17\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Bacteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/58/42921?source=see_link&amp;anchor=H2#H2\">",
"     \"Acute bacterial rhinosinusitis in children: Microbiology and treatment\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of a vaccine that is effective against both NTHi and Hib has the potential to reduce the burden of disease due to all types of",
"    <em>",
"     H. influenzae",
"    </em>",
"    . Identification of the ideal immunogen(s) requires further study. In addition, it is important to determine whether the prevention of mucosal infections involves protective antibodies. Since NTHi lack a polysaccharide capsule, type b anticapsular vaccines are not effective against NTHi infections. Vaccines effective against NTHi mucosal infections employ cell wall proteins as immunogens. Bacterial proteins that have been pursued as vaccine candidates include outer membrane proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/82-86\">",
"     82-86",
"    </a>",
"    ], adhesin molecules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/87-91\">",
"     87-91",
"    </a>",
"    ], and lipooligosaccharide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42489/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=see_link\">",
"       \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Vaccine",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active immunization of infants is the major means of prevention of",
"      <em>",
"       Haemophilus influenzae",
"      </em>",
"      type b (Hib) infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Immunization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Active immunization also leads to herd immunity such that high immunization levels reduce disease transmission even to the unimmunized. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Efficacy/effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend immunization of all infants with a Hib conjugate vaccine (",
"      <a class=\"graphic graphic_table graphicRef64312 \" href=\"mobipreview.htm?29/19/30012\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hib conjugate vaccine schedules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We also recommend catch-up immunization for children younger than five years who are unimmunized or underimmunized (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Catch-up schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that children who have invasive Hib disease before 24 months of age be immunized according to the age-appropriate schedule for unimmunized children (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Immunization should be initiated one month after the onset of invasive disease. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Previous history of invasive Hib disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Antimicrobial prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chemoprophylaxis of close contacts eradicates nasopharyngeal carriage of Hib, thereby reducing the risk of developing invasive disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      transmission. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antibiotic prophylaxis of close contacts'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/41/38549?source=see_link\">",
"       \"Pathogenesis and pathophysiology of bacterial meningitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To prevent invasive disease in susceptible children, we recommend chemoprophylaxis for close contacts of patients with invasive Hib disease who live in a household with a child who is younger than four years of age and has not received an age-appropriate number of doses of Hib conjugate vaccine, or an immunocompromised child (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hib conjugate vaccine schedules'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Close contact'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend chemoprophylaxis for child-care and preschool contacts when unimmunized or incompletely immunized children attend the facility and two or more cases of Hib invasive disease have occurred among attendees within 60 days (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Child care or preschool contacts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend chemoprophylaxis for the index patient if he or she was treated with an agent other than",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      and is younger than two years of age or lives in a household with a child &lt;4 years of age who has not received an age-appropriate number of doses of Hib conjugate vaccine, or an immunocompromised child (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hib conjugate vaccine schedules'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Index patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"       rifampin",
"      </a>",
"      for Hib chemoprophylaxis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The dose is 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum dose 600 mg) once per day for four days. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Recommended regimen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward eliminating Haemophilus influenzae type b disease among infants and children--United States, 1987-1997. MMWR Morb Mortal Wkly Rep 1998; 47:993.",
"     </a>",
"    </li>",
"    <li>",
"     Robbins JB, Schneerson R, Pittman M.. H. influenzae type b infections. In: Bacterial Vaccines, Germanier R (Ed), Academic Press, Orlando, FL 1984. p.290.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/3\">",
"      Tosi MF, Kaplan SL, Mason EO, et al. Generation of chemotactic activity in serum by Haemophilus influenzae type b. Infect Immun 1984; 43:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/4\">",
"      Tarr PI, Hosea SW, Brown EJ, et al. The requirement of specific anticapsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation. J Immunol 1982; 128:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/5\">",
"      Steele NP, Munson RS Jr, Granoff DM, et al. Antibody-dependent alternative pathway killing of Haemophilus influenzae type b. Infect Immun 1984; 44:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/6\">",
"      Newman SL, Waldo B, Johnston RB Jr. Separation of serum bactericidal and opsonizing activities for Haemophilus influenzae type b. Infect Immun 1973; 8:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/7\">",
"      Myerowitz RL, Norden CW. Immunology of the infant rat experimental model of Haemophilus influenzae type b meningitis. Infect Immun 1977; 16:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/8\">",
"      Fothergill LD, Wright J. Influenzal meningitis: the relation of age incidence to the bactericidal power of blood against the causal organism. J Immunol 1933; 24:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/9\">",
"      Johnston RB Jr, Anderson P, Rosen FS, Smith DH. Characterization of human antibody to polyribophosphate, the capsular antigen of Hemophilus influenzae, type B. Clin Immunol Immunopathol 1973; 1:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/10\">",
"      Norden CW. Prevalence of bactericidal antibodies to Haemophilus influenzae, type b. J Infect Dis 1974; 130:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/11\">",
"      Stull TL, Jacobs RF, Haas JE, et al. Human serum bactericidal activity against Haemophilus influenzae type b. J Gen Microbiol 1984; 130:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/12\">",
"      Peltola H, K&auml;yhty H, Virtanen M, M&auml;kel&auml; PH. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984; 310:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/13\">",
"      Peltola H, K&auml;yhty H, Sivonen A, M&auml;kel&auml; H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977; 60:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/14\">",
"      Granoff DM, Shackelford PG, Suarez BK, et al. Hemophilus influenzae type B disease in children vaccinated with type B polysaccharide vaccine. N Engl J Med 1986; 315:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/15\">",
"      Ward JI, Broome CV, Harrison LH, et al. Haemophilus influenzae type b vaccines: lessons for the future. Pediatrics 1988; 81:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/16\">",
"      Greenberg DP, Vadheim CM, Bordenave N, et al. Protective efficacy of Haemophilus influenzae type b polysaccharide and conjugate vaccines in children 18 months of age and older. JAMA 1991; 265:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/17\">",
"      Osterholm MT, Rambeck JH, White KE, et al. Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota. JAMA 1988; 260:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/18\">",
"      Berrington JE, Cant AJ, Matthews JN, et al. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose. Pediatrics 2006; 117:e717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/19\">",
"      Lee YC, Kelly DF, Yu LM, et al. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis 2008; 46:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/20\">",
"      Granoff DM, Anderson EL, Osterholm MT, et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 1992; 121:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/21\">",
"      Bulkow LR, Wainwright RB, Letson GW, et al. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr Infect Dis J 1993; 12:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/22\">",
"      Vella PP, Staub JM, Armstrong J, et al. Immunogenicity of a new Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB). Pediatrics 1990; 85:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/23\">",
"      Shapiro ED, Capobianco LA, Berg AT, Zitt MQ. The immunogenicity of Hemophilus influenzae type B polysaccharide-Neisseria meningitidis group B outer membrane protein complex vaccine in infants and young children. J Infect Dis 1989; 160:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/24\">",
"      Campbell H, Byass P, Ahonkhai VI, et al. Serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in very young Gambian infants. Pediatrics 1990; 86:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/25\">",
"      Ahonkhai VI, Lukacs LJ, Jonas LC, Calandra GB. Clinical experience with PedvaxHIB, a conjugate vaccine of Haemophilus influenzae type b polysaccharide--Neisseria meningitidis outer membrane protein. Vaccine 1991; 9 Suppl:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/26\">",
"      Yogev R, Arditi M, Chadwick EG, et al. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses. Pediatrics 1990; 85:690.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Haemophilus influenzae infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.345.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/28\">",
"      Galil K, Singleton R, Levine OS, et al. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J Infect Dis 1999; 179:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/29\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine. MMWR Morb Mortal Wkly Rep 2009; 58:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/30\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children. MMWR Morb Mortal Wkly Rep 2008; 57:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/31\">",
"      Miller MA, Meschievitz CK, Ballanco GA, Daum RS. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period. Pediatrics 1995; 95:522.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. News &amp; Events. FDA approves new combination vaccine that protects children against two bacterial diseases. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm308350.htm?utm_campaign=Google2&amp;utm_source=fdaSearch&amp;utm_medium=website&amp;utm_term=Menhibrix&amp;utm_content=1 (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     GSK receives FDA approval for MenHibrix. file://www.gsk.com/media/pressreleases/2012/2012-pressrelease-1134059.htm (Accessed on June 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/34\">",
"      Bryant KA, Marshall GS. Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers. Expert Rev Vaccines 2011; 10:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/35\">",
"      Marchant CD, Miller JM, Marshall GS, et al. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2010; 29:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/36\">",
"      Marshall GS, Marchant CD, Blatter M, et al. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States. Hum Vaccin 2011; 7:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/37\">",
"      Bryant K, McVernon J, Marchant C, et al. Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials. Hum Vaccin Immunother 2012; 8:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/38\">",
"      Bryant KA, Marshall GS, Marchant CD, et al. Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants. Pediatrics 2011; 127:e1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/39\">",
"      Centers for Disease Control and Prevention (CDC). Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep 2013; 62:52.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Active Immunization. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL  p.11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/41\">",
"      Trofa AF, Klein NP, Paul IM, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age. Pediatr Infect Dis J 2011; 30:e164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/42\">",
"      Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC. Prevention and control of meningococcal disease. MMWR Recomm Rep 2013; 62:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/43\">",
"      Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect Dis 2008; 8:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/44\">",
"      Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr 1992; 121:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/45\">",
"      Black SB, Shinefield HR, Fireman B, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J 1991; 10:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/46\">",
"      Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991; 324:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/47\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children--United States, 1998-2000. MMWR Morb Mortal Wkly Rep 2002; 51:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/48\">",
"      Cowgill KD, Ndiritu M, Nyiro J, et al. Effectiveness of Haemophilus influenzae type b Conjugate vaccine introduction into routine childhood immunization in Kenya. JAMA 2006; 296:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/49\">",
"      Scheifele DW, Bettinger JA, Halperin SA, et al. Ongoing control of Haemophilus influenzae type B infections in Canadian children, 2004-2007. Pediatr Infect Dis J 2008; 27:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/50\">",
"      Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/51\">",
"      Watt JP, Wolfson LJ, O'Brien KL, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009; 374:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/52\">",
"      Oh SY, Griffiths D, John T, et al. School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J Infect Dis 2008; 197:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/53\">",
"      Centers for Disease Control and Prevention (CDC). Interim recommendations for the use of Haemophilus influenzae type b (Hib) conjugate vaccines related to the recall of certain lots of Hib-containing vaccines (PedvaxHIB and Comvax). MMWR Morb Mortal Wkly Rep 2007; 56:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/54\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for use of Haemophilus influenzae type b (Hib) vaccine: reinstatement of the booster dose at ages 12-15 months. MMWR Morb Mortal Wkly Rep 2009; 58:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/55\">",
"      Centers for Disease Control and Prevention (CDC). Invasive Haemophilus influenzae Type B disease in five young children--Minnesota, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/56\">",
"      Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. Recommendations of the immunization practices advisory committee (ACIP). MMWR Recomm Rep 1991; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/57\">",
"      Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992; 120:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/58\">",
"      Kaplan SL, Duckett T, Mahoney DH Jr, et al. Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children with sickle hemoglobinopathy or malignancies, and after systemic Haemophilus influenzae type b infection. J Pediatr 1992; 120:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/59\">",
"      Frank AL, Labotka RJ, Rao S, et al. Haemophilus influenzae type b immunization of children with sickle cell diseases. Pediatrics 1988; 82:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/60\">",
"      ACIP Adult Immunization Work Group, Bridges CB, Woods L, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/61\">",
"      Edmonson MB, Granoff DM, Barenkamp SJ, Chesney PJ. Outer membrane protein subtypes and investigation of recurrent Haemophilus influenzae type b disease. J Pediatr 1982; 100:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/62\">",
"      Holmes SJ, Lucas AH, Osterholm MT, et al. Immunoglobulin deficiency and idiotype expression in children developing Haemophilus influenzae type b disease after vaccination with conjugate vaccine. The Collaborative Study Group. JAMA 1991; 266:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/63\">",
"      Centers for Disease Control and Prevention (CDC). Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2011; 60:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/64\">",
"      Ward JI, Fraser DW, Baraff LJ, Plikaytis BD. Haemophilus influenzae meningitis. A national study of secondary spread in household contacts. N Engl J Med 1979; 301:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/65\">",
"      Band JD, Fraser DW, Ajello G. Prevention of Hemophilus influenzae type b disease. JAMA 1984; 251:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/66\">",
"      Glode MP, Daum RS, Halsey NA, et al. Rifampin alone and in combination with trimethoprim in chemoprophylaxis for infections due to Haemophilus influenzae type b. Rev Infect Dis 1983; 5 Suppl 3:S549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/67\">",
"      Granoff DM, Gilsdorf J, Gessert C, Basden M. Haemophilus influenzae type B disease in a day care center: eradication of carrier state by rifampin. Pediatrics 1979; 63:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/68\">",
"      Glode MP, Daum RS, Boies EG, et al. Effect of rifampin chemoprophylaxis on carriage eradication and new acquisition of Haemophilus influenzae type b in contacts. Pediatrics 1985; 76:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/69\">",
"      Shapiro ED, Wald ER. Efficacy of rifampin in eliminating pharyngeal carriage of Haemophilus influenzae type b. Pediatrics 1980; 66:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/70\">",
"      Gessert C, Granoff DM, Gilsdorf J. Comparison of rifampin and ampicillin in day care center contacts of Haemophilus influenzae type b disease. Pediatrics 1980; 66:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/71\">",
"      Mason EO Jr, Kaplan SL, Lamberth LB, et al. Serotype and ampicillin susceptibility of Haemophilus influenzae causing systemic infections in children: 3 years of experience. J Clin Microbiol 1982; 15:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/72\">",
"      Ginsburg CM, McCracken GH Jr, Rae S, Parke JC Jr. Haemophilus influenzae type b disease. Incidence in a day-care center. JAMA 1977; 238:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/73\">",
"      Horner DB, McCracken GH Jr, Ginsburg CM, Zweighaft TC. A comparison of three antibiotic regimens for eradication of Haemophilus influenzae type b from the pharynx of infants and children. Pediatrics 1980; 66:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/74\">",
"      Yogev R, Melick C, Kabat K. Nasopharyngeal carriage of Haemophilus influenzae type b: attempted eradication by cefaclor or rifampin. Pediatrics 1981; 67:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/75\">",
"      Yogev R, Lander HB, Davis AT. Effect of TMP-SMX on nasopharyngeal carriage of ampicillin-sensitive and ampicillin-resistant hemophilus influenzae type B. J Pediatr 1978; 93:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/76\">",
"      Daum RS, Granoff DM, Gilsdorf J, et al. Haemophilus influenzae type b infections in day care attendees: implications for management. Rev Infect Dis 1986; 8:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/77\">",
"      Ogle JW, Rabalais GP, Glode MP. Duration of pharyngeal carriage of Haemophilus influenzae type b in children hospitalized with systemic infections. Pediatr Infect Dis 1986; 5:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/78\">",
"      Murphy TV, Del Rio MA, Chrane D. Persistent pharyngeal colonization during therapy in patients with meningitis caused by Haemophilus influenzae type b. J Infect Dis 1985; 152:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/79\">",
"      Goldwater PN. Effect of cefotaxime or ceftriaxone treatment on nasopharyngeal Haemophilus influenzae type b colonization in children. Antimicrob Agents Chemother 1995; 39:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/80\">",
"      Li KI, Wald ER. Use of rifampin in Haemophilus influenzae type b infections. Am J Dis Child 1986; 140:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/81\">",
"      Santosham M, Reid R, Ambrosino DM, et al. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. N Engl J Med 1987; 317:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/82\">",
"      Pittman M. THE ACTION OF TYPE-SPECIFIC HEMOPHILUS INFLUENZAE ANTISERUM. J Exp Med 1933; 58:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/83\">",
"      Barenkamp SJ, Munson RS Jr, Granoff DM. Subtyping isolates of Haemophilus influenzae type b by outer-membrane protein profiles. J Infect Dis 1981; 143:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/84\">",
"      Murphy TF, Dudas KC, Mylotte JM, Apicella MA. A subtyping system for nontypable Haemophilus influenzae based on outer-membrane proteins. J Infect Dis 1983; 147:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/85\">",
"      Murphy TF, Nelson MB, Dudas KC, et al. Identification of a specific epitope of Haemophilus influenzae on a 16,600-dalton outer membrane protein. J Infect Dis 1985; 152:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/86\">",
"      DeMaria TF, Murwin DM, Leake ER. Immunization with outer membrane protein P6 from nontypeable Haemophilus influenzae induces bactericidal antibody and affords protection in the chinchilla model of otitis media. Infect Immun 1996; 64:5187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/87\">",
"      St Geme JW 3rd. The pathogenesis of nontypable Haemophilus influenzae otitis media. Vaccine 2000; 19 Suppl 1:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/88\">",
"      Barenkamp SJ, Leininger E. Cloning, expression, and DNA sequence analysis of genes encoding nontypeable Haemophilus influenzae high-molecular-weight surface-exposed proteins related to filamentous hemagglutinin of Bordetella pertussis. Infect Immun 1992; 60:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/89\">",
"      Winter LE, Barenkamp SJ. Human antibodies specific for the high-molecular-weight adhesion proteins of nontypeable Haemophilus influenzae mediate opsonophagocytic activity. Infect Immun 2003; 71:6884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/90\">",
"      Barenkamp SJ, St Geme JW 3rd. Identification of a second family of high-molecular-weight adhesion proteins expressed by non-typable Haemophilus influenzae. Mol Microbiol 1996; 19:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/91\">",
"      Cutter D, Mason KW, Howell AP, et al. Immunization with Haemophilus influenzae Hap adhesin protects against nasopharyngeal colonization in experimental mice. J Infect Dis 2002; 186:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42489/abstract/92\">",
"      Gu XX, Sun J, Jin S, et al. Detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins confers protection against otitis media in chinchillas. Infect Immun 1997; 65:4488.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6022 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-27C422A60D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_31_42489=[""].join("\n");
var outline_f41_31_42489=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMMUNIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Conjugate vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hib conjugate vaccine dose and route",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hib conjugate vaccine schedules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Efficacy/effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Contraindications and precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Special uses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Catch-up schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Impaired host defense",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Previous history of invasive Hib disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86826243\">",
"      - Combination Hib-meningococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INFECTION CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ANTIBIOTIC PROPHYLAXIS OF CLOSE CONTACTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Close contact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H69447014\">",
"      Monitoring for illness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Child care or preschool contacts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Index patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Recommended regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PASSIVE IMMUNIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      NONTYPEABLE H. INFLUENZAE (NTHi) VACCINE CANDIDATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Antimicrobial prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6022\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6022|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/19/30012\" title=\"table 1\">",
"      Hib conjugate vaccines US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/59/6077\" title=\"table 2\">",
"      Hib schedule US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/48/9999\" title=\"table 3\">",
"      Meningococcal vaccination indications in the US",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/58/42921?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Microbiology and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/55/2938?source=related_link\">",
"      Epidemiology, pathogenesis, and etiology of pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13258?source=related_link\">",
"      IgG subclass deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41608?source=related_link\">",
"      Microbiology, epidemiology and treatment of Haemophilus influenzae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/41/38549?source=related_link\">",
"      Pathogenesis and pathophysiology of bacterial meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_31_42490="Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults";
var content_f41_31_42490=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/31/42490/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/31/42490/contributors\">",
"     Andre A Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/31/42490/contributors\">",
"     James N George, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/31/42490/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/31/42490/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/31/42490/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/31/42490/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/31/42490/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) in the adult will be discussed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Discussions of the causes and diagnosis of TTP-HUS in adults, and of the treatment of HUS in children, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30649?source=see_link\">",
"     \"Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DISEASE OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are systemic disorders characterized by endothelial injury and the formation of small vessel platelet rich thrombi. The resulting thrombotic microangiopathy produces microangiopathic hemolytic anemia and thrombocytopenia; presenting features may also include neurologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal abnormalities.",
"   </p>",
"   <p>",
"    Although some studies appear to distinguish between TTP and HUS in adults, the presenting features are essentially the same in most patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a few patients, neurologic abnormalities are dominant and renal failure is minimal or not present; these patients are considered by some to represent TTP.",
"     </li>",
"     <li>",
"      When renal failure is dominant and neurologic abnormalities are minimal or absent, the disorder is considered by some to represent HUS.",
"     </li>",
"     <li>",
"      Some patients present with severe neurologic abnormalities (eg, focal neurologic abnormalities, seizures, coma) together with renal failure.",
"     </li>",
"     <li>",
"      Many patients have neither neurologic nor renal function abnormalities. For example, approximately one-half of our patients with TTP-HUS associated with a severe (ie, &lt;10 percent) deficiency of ADAMTS13 activity had no or minimal neurologic abnormalities and no evidence for renal failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, these patients can be best described by the comprehensive term TTP-HUS. However, all such patients are diagnosed via the presence of thrombocytopenia and microangiopathic hemolytic anemia (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"mobipreview.htm?37/50/38694\">",
"     picture 1",
"    </a>",
"    ) without another clinically apparent cause. Further, the pathologic features are identical in any case (",
"    <a class=\"graphic graphic_picture graphicRef63511 graphicRef54840 graphicRef69687 graphicRef78330 graphicRef75317 \" href=\"mobipreview.htm?43/7/44154\">",
"     picture 2A-E",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Treatment with plasma exchange was established in a clinical trial that randomly assigned patients to receive either plasma exchange or plasma infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/7\">",
"     7",
"    </a>",
"    ]. This trial excluded patients with renal failure because of the risk of volume overload. Since patients with severe renal failure rarely have severe ADAMTS13 deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/8\">",
"     8",
"    </a>",
"    ], this clinical trial has been interpreted to document that plasma exchange is effective in patients with severe ADAMTS13 deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6921030\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;If untreated, TTP-HUS in adults typically follows a progressive course in which irreversible renal failure, progressive neurologic deterioration, cardiac ischemia, and death are common outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. The mortality rate prior to the use of plasma exchange was approximately 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/3,11,12\">",
"     3,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mainstay of treatment for most patients with TTP-HUS is plasma exchange, which in the context of this syndrome refers to the removal of the patient&rsquo;s plasma by pheresis and the replacement with donor plasma rather than another replacement fluid such as albumin. Compared with the mortality rate of 90 percent prior to the use of plasma exchange, the mortality rate for patients treated with plasma exchange is 25 percent or less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/7,12-15\">",
"     7,12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma exchange should be initiated even if there is some uncertainty about the diagnosis of TTP-HUS, as it is considered that the potential dangers of rapid deterioration from TTP-HUS exceed the significant risks of plasma exchange treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/1,9,16,17\">",
"       1,9,16,17",
"      </a>",
"      ]. If an alternative diagnosis is subsequently discovered (eg, systemic infection, disseminated malignancy, malignant hypertension), plasma exchange should then be stopped (",
"      <a class=\"graphic graphic_algorithm graphicRef69258 \" href=\"mobipreview.htm?4/62/5088\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Complications'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      There may be an inappropriate delay in considering the diagnosis of TTP-HUS and initiating plasma exchange. This is a particular problem when TTP-HUS develops in a patient who is already hospitalized for another established problem, such as hemorrhagic colitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/18\">",
"       18",
"      </a>",
"      ], recent surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/19\">",
"       19",
"      </a>",
"      ], acute pancreatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/20\">",
"       20",
"      </a>",
"      ], or other conditions that may trigger the onset of an acute episode of TTP-HUS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link&amp;anchor=H11#H11\">",
"       \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Plasma exchange reverses the microvascular thrombus formation and the resulting symptoms characteristic of TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/7,9,21-26\">",
"     7,9,21-26",
"    </a>",
"    ]. In many cases of idiopathic TTP-HUS, these microvascular thrombi form because a specific von Willebrand factor-cleaving protease, ADAMTS13, becomes depleted through the activity of an autoantibody. Severely reduced ADAMTS13 activity results in the accumulation of unusually large von Willebrand factor (VWF) multimers, which cause platelet aggregation and deposition of platelet-rich thrombi in tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/9,10,27,28\">",
"     9,10,27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H7#H7\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasma exchange reverses these processes in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Removal of the patient's plasma depletes the circulating autoantibody to ADAMTS13 (when present) and the circulating very high molecular weight VWF multimers.",
"     </li>",
"     <li>",
"      Infusion of donor plasma supplies the missing ADAMTS13 protease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systemic anticoagulation is not a component of TTP-HUS treatment. However, if anticoagulation is required (eg, for venous thromboembolism), the presence of TTP-HUS is not a contraindication to its use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=see_link&amp;anchor=H22#H22\">",
"     \"Catheter-induced upper extremity venous thrombosis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7729522\">",
"    <span class=\"h2\">",
"     Plasma exchange indications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Idiopathic TTP-HUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic TTP-HUS refers to TTP-HUS without an obvious inciting event, such as diarrheal illness, other infection, or new medication. Idiopathic TTP-HUS is a",
"    <strong>",
"     medical emergency",
"    </strong>",
"    that is almost always fatal if appropriate treatment is not initiated promptly. Accordingly, all patients suspected of having idiopathic TTP-HUS should be admitted without delay to a medical center capable of performing plasma exchange and treated on an urgent basis with plasma exchange, rather than with plasma infusion or the use of immunosuppressive agents alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13594392\">",
"    <span class=\"h4\">",
"     Plasma exchange versus plasma infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma exchange was found to be superior to plasma infusion in the treatment of the vast majority of adults with TTP-HUS in two landmark trials that included 210 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/7,23\">",
"     7,23",
"    </a>",
"    ]. The results of these studies, which yielded much better results than previously seen in untreated subjects, can be summarized as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial involving 102 patients with TTP-HUS, plasma exchange with fresh frozen plasma was more effective than plasma infusion alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/7\">",
"       7",
"      </a>",
"      ]. At six months, the remission and survival rates with these two procedures were 78 versus 31 percent (remission) and 78 versus 50 percent (survival). The mortality rate was much higher in nonresponders to either of these interventions.",
"     </li>",
"     <li>",
"      Patients treated with plasma exchange received approximately three times as much plasma as those treated with plasma infusion alone, since the degree of plasma administration was limited by the risk of volume overload in the latter group. Thus, the apparent enhanced benefit from plasma exchange may have been due to infusion of more plasma rather than to the removal of a toxic substance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Plasma exchange is more effective than plasma infusion in most adults with &ldquo;classical&rdquo; TTP-HUS because for the great majority of those who have decreased ADAMTS13 activity, the decreased activity is due to an inhibitory antibody. Plasma exchange both removes the inhibitory antibody and supplies replacement ADAMTS13 from the donor plasma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H7#H7\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6921030\">",
"     'Overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although less effective than plasma exchange [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/7,12,30\">",
"     7,12,30",
"    </a>",
"    ], and potentially complicated by volume overload, a retrospective analysis at one medical center indicated that high dose plasma infusion (25 to 30",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per day) was",
"    <strong>",
"     temporarily",
"    </strong>",
"    effective in some patients with TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/31\">",
"     31",
"    </a>",
"    ]. Plasma infusion without exchange, if tolerated, might therefore serve as emergency initial treatment in those not having immediate access to plasma exchange [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For rare cases of individuals who are known to have congenital ADAMTS13 deficiency due to a mutation in the gene encoding ADAMTS13 (ie, Upshaw-Schulman syndrome), plasma infusion supplies the missing protein and is sufficient treatment; plasma exchange is not required. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link&amp;anchor=H13964768#H13964768\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Congenital TTP'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10314900\">",
"     'Congenital TTP'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13594423\">",
"    <span class=\"h4\">",
"     Measurement of ADAMTS13 activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of using information concerning ADAMTS13 for initial diagnosis and treatment decisions remains uncertain, especially since such results may not be available for several days, well after initial treatment decisions need to be made. Also, ADAMTS13 activity measured by different methods (eg, using a synthetic substrate versus intact von Willebrand factor) may have discrepant results in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It has been concluded that the group of patients with severe ADAMTS13 deficiency does not include all patients who may respond to plasma exchange [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/8\">",
"       8",
"      </a>",
"      ], and that persistence of ADAMTS13 deficiency with or without inhibitory antibody activity following plasma exchange may still be consistent with an excellent clinical response to treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ADAMTS13 measurements appear to be of greatest clinical value for estimating the prognosis for relapse after recovery from an acute episode, for initial treatment of a patient who has an acute, recurrent episode, and perhaps also for helping to distinguish the different mechanisms of thrombotic microangiopathy in complex clinical situations. Patients with an ADAMTS13 activity &gt;10 percent at the time of their initial presentation rarely relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/10,15,33,34\">",
"       10,15,33,34",
"      </a>",
"      ]. However the clinical importance of ADAMTS13 measurements during remission is unknown. Approximately 20 percent of patients will have persistent ADAMTS13 deficiency that may not predict a risk for relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H107006957\">",
"       'Prognosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ADAMTS13 activity can be low due to an inherited defect or an acquired inhibitor, such as an autoantibody. However, the absence of a demonstrable ADAMTS13 inhibitor does not exclude the diagnosis of acquired, autoimmune TTP-HUS. The titer of ADAMTS13 inhibitors may be too low to be observed in a plasma mixing study, or may have been neutralized by multiple transfusions prior to obtaining a sample. An acquired autoimmune etiology, rather than a congenital deficiency of ADAMTS13, is documented by recovery of ADAMTS13 activity to normal during remission or by documenting the presence of an inhibitor at the time of a relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations support the current practice of requiring",
"    <strong>",
"     only",
"    </strong>",
"    thrombocytopenia and microangiopathic hemolytic anemia with no other apparent cause in order to make a clinical diagnosis of TTP-HUS and initiate prompt treatment with plasma exchange in appropriate scenarios.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780433\">",
"    <span class=\"h4\">",
"     Measurement of complement levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in complement proteins can cause congenital HUS, a recognized pediatric condition considered to be a form of atypical HUS (aHUS), distinct from the much more common childhood HUS resulting from an enteric infection with E. coli O157:H7 or other Shiga toxin-secreting bacteria. It is reasonable to measure complement levels (ie, C3 and C4) in patients presenting with a TTP-HUS syndrome prior to initiating plasma exchange, as these may be informative if ADAMTS13 levels are found to be low or if there is a nephritic picture, although there are no clinical data to guide this practice. Once plasma exchange has been initiated, it becomes difficult to test complement levels because complement proteins from donor plasma will be present. In contrast, genetic testing for complement mutations will only detect genetic forms of aHUS, and is unlikely to be informative in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=see_link&amp;anchor=H7#H7\">",
"     \"Atypical hemolytic uremic syndrome in children\", section on 'Genetic forms of HUS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Adult typical (diarrheal) HUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical HUS refers to HUS in adults or children associated with diarrhea, typically caused by Shiga toxin-producing Escherichia coli. The treatment of this syndrome in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30649?source=see_link\">",
"     \"Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The appropriate treatment of typical (ie, post-diarrheal) HUS due to Shiga toxin-producing E. coli in adults is unresolved. Uncontrolled observations have provided mixed results regarding the efficacy of plasma exchange, as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, 6 of 22 adults with HUS due to E. coli O157 had contraindications to plasma exchange or died before plasma exchange could be performed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/35\">",
"       35",
"      </a>",
"      ]. Among the 16 patients who received plasma exchange, there were only five deaths (31 percent), including only one in eight patients under age 70.",
"     </li>",
"     <li>",
"      Another case series of adult patients who presented with overt bloody diarrhea and presumed E. coli O157 infection reported that 17 of the 21 apparently responded to plasma exchange treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/18\">",
"       18",
"      </a>",
"      ]. Two of these 21 patients had severe ADAMTS13 deficiency (ie, activity &lt;5 percent), indicating that patients with severe ADAMTS13 deficiency may present with bloody diarrhea, presumably due to intestinal ischemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective analysis of 298 patients who developed HUS following infection with E. Coli O104:H4 in May 2011 in Germany, 84 percent were treated with plasma exchange [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/36\">",
"       36",
"      </a>",
"      ]. The mean number of sessions was 7.3. When compared with patients from the same epidemic who did not receive plasma exchange, patients treated with plasma exchange had a lower mortality (4 of 47 versus 8 of 251 deaths). Compared with those who did not receive plasma exchange, patients treated with plasma exchange were more likely to require dialysis, to need ventilatory support, and to have seizures (13 versus 61 percent, 9 versus 20 percent, and 6 versus 14 percent, respectively). While smaller reports from this same epidemic suggested that plasma exchange was effective in improving clinical outcomes (eg, platelet count, renal function, and neurologic status) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/37\">",
"       37",
"      </a>",
"      ], this larger report did not show a clear benefit from plasma exchange for typical HUS in adults. Interpretation of this study is complicated by the more consistent use of plasma exchange for patients with severe disease compared with those with milder disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of a randomized trial, our approach continues to include a low threshold for plasma exchange in all adults who appear to have typical HUS, especially if neurologic symptoms are severe. Our rationale for this approach is that since almost all cases of HUS caused by Shiga toxin-producing E. coli are sporadic (ie, not associated with an outbreak), the etiology cannot be known at the time of presentation and the possibility of severe ADAMTS13 deficiency cannot be excluded. Other supportive measures for the treatment of adult typical HUS (eg, dialysis) are similar to those employed in children with typical HUS, and are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30649?source=see_link\">",
"     \"Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5534574\">",
"    <span class=\"h4\">",
"     Eculizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/63/28662?source=see_link\">",
"     Eculizumab",
"    </a>",
"    is a humanized monoclonal antibody directed against the complement component C5. Administration of eculizumab prevents the cleavage of C5 into C5a and C5b, and it inhibits terminal complement activation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11190?source=see_link&amp;anchor=H10#H10\">",
"     \"Complement pathways\", section on 'Alternative pathway'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/63/28662?source=see_link\">",
"     Eculizumab",
"    </a>",
"    has shown efficacy in children and adults with",
"    <strong>",
"     congenital",
"    </strong>",
"    complement abnormalities that result in excessive complement activation (ie, atypical HUS). (See",
"    <a class=\"local\" href=\"#H1991633\">",
"     'Atypical HUS in adults'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=see_link&amp;anchor=H15#H15\">",
"     \"Atypical hemolytic uremic syndrome in children\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anecdotal information indicates that many of the",
"    <strong>",
"     adult",
"    </strong>",
"    patients with",
"    <strong>",
"     typical",
"    </strong>",
"    HUS due to an outbreak of E. coli O104:H4 infection in Germany had been treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    in addition to plasma exchange when severe central nervous system involvement was present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, a retrospective analysis of 67 patients from this outbreak who were treated with eculizumab compared with 65 controls from the same epidemic with similar clinical severity who did not receive eculizumab found no evidence of improved outcomes in the eculizumab treated patients (eg, platelet recovery, anemia, renal function, neurologic complications, or death) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/36\">",
"     36",
"    </a>",
"    ]. Use of eculizumab in adults with typical HUS is investigational.",
"   </p>",
"   <p>",
"    Some patients with typical HUS have an especially severe course and are challenging to manage.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/63/28662?source=see_link\">",
"     Eculizumab",
"    </a>",
"    could be appropriate in patients with normal ADAMTS13 activity who have not shown improvement after two weeks of daily plasma exchange. There are insufficient data to guide therapy based on complement testing. Additional concerns with this approach include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cost",
"     </li>",
"     <li>",
"      Decisions about discontinuing therapy are challenging, because it may be difficult to distinguish whether patient improvement while on therapy is in fact due to the therapy.",
"     </li>",
"     <li>",
"      Plasmapheresis removes",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/63/28662?source=see_link\">",
"       eculizumab",
"      </a>",
"      from the circulation, which will impair its effectiveness. Thus, plasma exchange should be avoided after eculizumab administration, and if plasma exchange is continued, supplemental doses of eculizumab are required [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5534581\">",
"    <span class=\"h4\">",
"     Immunoadsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoadsorption refers to a modification of apheresis in which immunoglobulins and other proteins are removed from a patient&rsquo;s plasma by passing the plasma over a column. Twelve patients with typical HUS due to an outbreak of E. Coli P104:H4 had complications (eg, severe kidney injury requiring renal replacement therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delayed neurologic complications necessitating mechanical ventilation) that did not improve in response to plasma exchange or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/39\">",
"     39",
"    </a>",
"    ]. All 12 were enrolled in a prospective, uncontrolled, compassionate use trial of IgG immunoadsorption using a protein A column. All 12 patients survived, 10 with complete recovery of neurologic and renal function. Protein A columns for immunoadsorption are not generally available outside of a research setting, and this particular type of regenerating immunoadsorption column system is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Exceptions to the use of plasma exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are",
"    <strong>",
"     two exceptions",
"    </strong>",
"    to the general recommendation of plasma exchange in TTP-HUS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Postdiarrheal HUS in children",
"      </strong>",
"      &mdash; The typical diarrhea-associated HUS of young children is most often caused by enteric infection by E. coli O157:H7 and usually resolves spontaneously, following supportive therapy alone. Plasma exchange may be considered in patients with severe neurologic abnormalities or persistent disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30649?source=see_link\">",
"       \"Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cancer chemotherapy or hematopoietic cell transplantation",
"      </strong>",
"      &mdash; There are only sporadic and anecdotal reports that suggest efficacy of plasma exchange for syndromes that appear similar to TTP and HUS following cancer chemotherapy or hematopoietic cell transplantation (HCT) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/40-42\">",
"       40-42",
"      </a>",
"      ]. Syndromes of thrombotic microangiopathy (TMA) that occur after cancer chemotherapy or HCT may be the result of dose-dependent drug toxicity to the kidneys and other organs. For patients post-allogeneic HCT, systemic infections or acute graft-versus-host disease are the usual etiologies for microangiopathic hemolytic anemia and thrombocytopenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Avoidance of unnecessary plasma exchange in HCT patients has been facilitated by describing these disorders as \"transplantation-associated TMA\" rather than TTP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/43\">",
"     43",
"    </a>",
"    ], since the diagnosis of TTP triggers immediate consideration of plasma exchange treatment.",
"   </p>",
"   <p>",
"    If plasma exchange treatment is not begun and there is no spontaneous improvement or no alternative etiology is discovered, a short, defined course of plasma exchange (eg, five days) may be entertained. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1609?source=see_link&amp;anchor=H10#H10\">",
"     \"Kidney disease following hematopoietic cell transplantation\", section on 'Treatment and prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H22#H22\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Chemotherapy agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppression with glucocorticoids may be a useful addition to plasma exchange therapy for some patients with TTP-HUS (ie, those who are producing an autoantibody that interferes with ADAMTS13 activity or endothelial cell function). Although documentation of an anti-ADAMTS13 antibody may identify patients who might benefit from adjunctive treatment with immunosuppressive agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], this information is not generally available when initial treatment decisions must be made. Accordingly, clinical features are the appropriate measures to guide initial therapy with glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient has idiopathic TTP-HUS (ie, no evidence for a drug-induced etiology, no bloody diarrheal prodrome, no severe renal failure), it is likely that the disorder has an autoimmune etiology. Although not tested in a randomized setting, adjunctive immunosuppressive treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day by mouth) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (125 mg IV twice daily) is reasonable for such patients, as well as for those with a poor response to initial treatment with plasma exchange [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/1,5\">",
"       1,5",
"      </a>",
"      ]. (",
"      <a class=\"graphic graphic_algorithm graphicRef69258 \" href=\"mobipreview.htm?4/62/5088\">",
"       algorithm 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      In patients whose platelet counts do not increase within several days of treatment with plasma exchange, or those in whom thrombocytopenia recurs when plasma exchange treatments are diminished or discontinued, addition of glucocorticoids is also appropriate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/1\">",
"       1",
"      </a>",
"      ] (",
"      <a class=\"graphic graphic_algorithm graphicRef69258 \" href=\"mobipreview.htm?4/62/5088\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with a more severe or prolonged clinical course may benefit from further immunosuppression with the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      to plasma exchange. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Rituximab'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study, initiated in 1979, indicated that some patients with minimal symptoms and no neurologic abnormalities or marked renal disease responded to treatment with 200 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    per day without the use of plasma exchange [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/23\">",
"     23",
"    </a>",
"    ]. Lack of rise in the platelet count by 48 hours was an indication to add plasma exchange. However, such initial treatment with prednisone ALONE is non-standard and the recommendation is that immediate plasma exchange is necessary when the diagnosis of TTP-HUS is made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Platelet transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anecdotal reports have suggested that platelet transfusion may lead to new or worsening neurologic symptoms and to acute renal failure, presumably due to the production of new or expanding microvascular thrombi as the infused platelets are consumed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/23,46,47\">",
"     23,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a systematic literature review as well as a review of the clinical course of 54 consecutive patients with severe ADAMTS13 deficiency (activity &lt;10 percent) from the Oklahoma TTP-HUS Registry concluded that evidence for harm from platelet transfusions in patients with TTP is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/48\">",
"     48",
"    </a>",
"    ]. Accordingly, if platelet transfusions are required, either for bleeding or in preparation for an invasive procedure, the clinician should be aware of the potential risk for adverse effects, but should not avoid the appropriate use of such transfusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10315058\">",
"    <span class=\"h2\">",
"     Ineffective initial treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiplatelet agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    ) are not effective when given alone for TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/49\">",
"     49",
"    </a>",
"    ], although they may be of benefit when added to plasma exchange [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/7\">",
"     7",
"    </a>",
"    ]. However, administration of antiplatelet agents can induce or aggravate bleeding in these thrombocytopenic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/49\">",
"     49",
"    </a>",
"    ]. Accordingly, if aspirin is used as adjunctive treatment, it should be limited to those with platelet counts",
"    <span class=\"nowrap\">",
"     &gt;50,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anticoagulants have not been used to treat the microvascular thrombi of TTP-HUS, which are mostly composed of platelets rather than fibrin. Anticoagulants should be reserved for the treatment and prevention of large vessel thromboembolic disease only if indicated for reasons other than TTP-HUS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PLASMA EXCHANGE PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Here we discuss plasma exchange as treatment for TTP-HUS. A more comprehensive overview of the procedure is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Available plasma products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large volumes of plasma are needed for the treatment of a patient with TTP, estimated to be approximately 115 units per treatment course in a 60 kg patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/50\">",
"     50",
"    </a>",
"    ], potentially increasing the risk of transfusion-related complications (eg, infection, volume overload).",
"   </p>",
"   <p>",
"    A number of different plasma products have been evaluated in terms of both efficacy and safety for the treatment of TTP and are discussed below. In two small studies, the concentration of ADAMTS13 was similar in samples of freshly obtained plasma, fresh frozen plasma, cryosupernatant plasma, and 24-hour plasma products over five days of storage at 1 to 6&deg;C, as well as",
"    <span class=\"nowrap\">",
"     solvent/detergent-treated",
"    </span>",
"    plasma from two different suppliers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Fresh frozen plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large volumes of fresh frozen plasma (FFP) (approximately four units per liter of plasma removed) from many different donors are required during plasma exchange, increasing the risk of anaphylactoid reactions. Patients with severe and repetitive reactions to fresh frozen plasma can be pretreated with ephedrine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6646?source=see_link\">",
"     \"Complications of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Cryoprecipitate-poor plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of FFP replacement may be lessened because of its content of von Willebrand factor (VWF) multimers, which might promote the formation of more platelet thrombi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/54\">",
"     54",
"    </a>",
"    ]. If true, the cryosupernatant fraction of plasma (cryoprecipitate-reduced, cryoprecipitate poor plasma, cryo-poor plasma) might be more effective, since VWF is largely removed in the cryoprecipitate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/22,55,56\">",
"     22,55,56",
"    </a>",
"    ]. However, two small randomized, controlled trials found no difference in efficacy between whole plasma and cryoprecipitate-poor plasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If cryosupernatant plasma is used, deficiencies of fibrinogen and factor VIII, which are removed during this process, should be prevented by the intermittent use of whole plasma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11895?source=see_link&amp;anchor=H16#H16\">",
"     \"Preparation of blood components\", section on 'Cryoprecipitate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Viral inactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of methodologies for viral inactivation of plasma are available, including the",
"    <span class=\"nowrap\">",
"     solvent/detergent",
"    </span>",
"    method (SDP), as well as the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    or amotosalen, followed by photoactivation. Some of these have been employed in patients with TTP, and are discussed below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38247?source=see_link\">",
"     \"Pathogen inactivation of blood products\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Solvent-detergent method &mdash; In one small randomized study and a number of anecdotal reports, the use of SDP appeared as effective as FFP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/59-63\">",
"       59-63",
"      </a>",
"      ]. However, concerns have been raised about potential thrombotic complications from the use of SDP in TTP and other disorders of coagulation, due to the reduced protein S levels in this product [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38247?source=see_link&amp;anchor=H9#H9\">",
"       \"Pathogen inactivation of blood products\", section on 'Solvent-detergent method'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Amotosalen-UVA method &mdash; A randomized trial compared treatment with",
"      <span class=\"nowrap\">",
"       amotosalen/ultraviolet",
"      </span>",
"      A light-treated FFP with FFP in 35 patients with TTP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/50\">",
"       50",
"      </a>",
"      ]. Although this study was not sufficiently powered to detect small differences, the rates of attainment of remission within 30 days, relapse rates, number of plasma units exchanged, improvement in ADAMTS13 levels and inhibitors, and adverse events were similar for both treatment groups.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"       Methylene blue",
"      </a>",
"      method &mdash; In one retrospective report, use of FFP virally inactivated with methylene blue and photoactivation (MBP), as compared with the use of FFP, resulted in a slightly lower complete remission rate, required a greater number of plasma exchanges, and resulted in a longer hospital stay [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/66\">",
"       66",
"      </a>",
"      ]. In two additional reports comparing MBP to FFP, those receiving MBP had an increased risk of dying from progressive TTP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/67\">",
"       67",
"      </a>",
"      ], a greater number of recurrences [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/67,68\">",
"       67,68",
"      </a>",
"      ], and a lower probability of attaining a sustained remission within eight to nine days of starting plasma exchange [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38247?source=see_link&amp;anchor=H14#H14\">",
"       \"Pathogen inactivation of blood products\", section on 'Methylene blue method'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data and observations outlined above suggest that most plasma products are equally effective for the treatment of TTP.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"     Methylene blue",
"    </a>",
"    -treated plasma appears to be an exception, as the available data suggest that it is less effective than the other available plasma products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Schedule",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Daily exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma exchange is initially performed daily until the platelet count has normalized and hemolysis largely ceased, as evidenced by a return of the serum lactate dehydrogenase (LDH) concentration to normal, or nearly normal, levels (",
"    <a class=\"graphic graphic_algorithm graphicRef69258 \" href=\"mobipreview.htm?4/62/5088\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/1,33\">",
"     1,33",
"    </a>",
"    ]. On average, 7 to 16 daily exchanges are required to induce remission, but the variability is large and unpredictable, ranging from 3 to 145 required exchanges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/4,7,23,69,70\">",
"     4,7,23,69,70",
"    </a>",
"    ]. The recommended volume to be exchanged at each procedure is one estimated plasma volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serial observations indicate that neurologic symptoms and the serum concentration of lactate dehydrogenase (LDH) tend to improve first (one to three days) and the platelet count starts to rise after several days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/21\">",
"     21",
"    </a>",
"    ]. Improvement in renal function is unpredictable and often incomplete. Even patients who require dialysis during the acute episode (16 percent in one report) generally recover sufficient function to be able to discontinue dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/71\">",
"     71",
"    </a>",
"    ]. However, many patients have a residual impairment in renal function",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistent hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/71-75\">",
"     71-75",
"    </a>",
"    ]. These abnormalities are often not indicative of active disease or the need for continued plasma exchange (see",
"    <a class=\"local\" href=\"#H107007014\">",
"     'Long-term outcome'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Whether continued plasma exchanges influences recovery of renal function, once thrombocytopenia and hemolysis have been corrected, is unknown. This is an important problem since many patients have residual renal insufficiency.",
"   </p>",
"   <p>",
"    When a normal platelet count has been achieved, plasma exchange may be discontinued abruptly or gradually tapered by increasing the interval between treatments. The practice of tapering plasma exchange treatments was established to prevent TTP exacerbations. However, exacerbations are uncommon when plasma exchange is accompanied by the use of corticosteroids and the additional use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for patients with a more severe clinical course. Therefore, abruptly stopping plasma exchange treatments is becoming the more common practice. Abruptly stopping plasma exchange has the advantage of potentially reducing the number of days the central venous catheter is in place, thereby reducing the risks of catheter-related infections. Abruptly stopping plasma exchange does not always imply immediate removal of the central venous catheter. (See",
"    <a class=\"local\" href=\"#H3004372\">",
"     'Central catheter issues'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with severe ADAMTS13 deficiency may have a prompt exacerbation of thrombocytopenia and hemolysis when daily plasma exchanges are tapered or stopped, requiring reinstitution of daily exchanges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/76\">",
"     76",
"    </a>",
"    ]. These episodes are described as exacerbations of a continuing episode of TTP-HUS, rather than as relapses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/8\">",
"     8",
"    </a>",
"    ]. In these patients, a tapering schedule of plasma exchange treatments and additional immunosuppressive treatment are appropriate. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Immunosuppressive agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3004372\">",
"    <span class=\"h3\">",
"     Central catheter issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once plasma exchange is discontinued, a jugular or subclavian vein catheter is typically left in place for three to seven days, during which the patient is monitored. If ongoing evaluation demonstrates no rapid drop in platelets or rise in LDH, the catheter is removed. This practice avoids the risks associated with placement of a new catheter if an early exacerbation occurs. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Complications'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/1/29?source=see_link\">",
"     \"Complications of central venous catheters and their prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, femoral vein catheters, which are more prone to infection, are removed as soon as possible. Even if plasma exchange is ongoing, a femoral vein catheter should be left in place no longer than five to seven days in total due to the infectious risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44553?source=see_link&amp;anchor=H1382365406#H1382365406\">",
"     \"Overview of central venous access\", section on 'Femoral access versus other sites'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Location'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Twice-daily exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a few of our patients, twice daily plasma exchange was initiated because of failure to respond to the initial daily plasma exchange or exacerbation of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/70,77\">",
"     70,77",
"    </a>",
"    ]. Because other treatments were initiated or intensified in such patients, the specific benefit of twice-daily exchange could not be clearly documented in most patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 3 of 31 episodes twice-daily exchange was documented to be definitely beneficial; all three patients had low levels of ADAMTS13 along with an inhibitor.",
"     </li>",
"     <li>",
"      In the one fatality with no response to twice-daily exchange, the patient was subsequently determined to have had Rocky Mountain Spotted Fever rather than TTP-HUS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest increasing the frequency of plasma exchange to twice daily for patients with refractory or recurrent TTP-HUS (ie, who have a severe course, do not rapidly respond to plasma exchange, worsen with neurologic abnormalities despite plasma exchange plus corticosteroids, or have relapsing disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section discusses complications of plasma exchange for the treatment of TTP-HUS. A more general discussion of complications of plasma exchange is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6646?source=see_link\">",
"     \"Complications of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10316266\">",
"    <span class=\"h3\">",
"     Central venous catheter and plasma complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major complications of plasma exchange occur in approximately one-quarter of patients with TTP-HUS. There are two major types of major complications from plasma exchange: those related to the use of the central venous catheter, and those due to the plasma itself; catheter-related complications tend to be the more life-threatening of the two.",
"   </p>",
"   <p>",
"    Data regarding the frequency of plasma exchange complications in this population largely come from the Oklahoma TTP-HUS registry, which has reported data from consecutive patients presenting to 12 hospitals in the region, with review at three-year intervals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/16,17,78-80\">",
"     16,17,78-80",
"    </a>",
"    ]. In an overview of 302 patients referred for plasma exchange from 1996 to 2011, major complications were defined as those that prompted additional hospitalization or intensive care unit transfer; or that led to a new invasive procedure, systemic treatment, or red blood cell transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/80\">",
"     80",
"    </a>",
"    ]. Seven patients died due to complications of plasma exchange: four from sepsis and three from catheter insertion (hemorrhage, pneumothorax). Major complications occurred in 24 percent of patients, the majority due to the central venous catheter:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection - 12 percent",
"     </li>",
"     <li>",
"      Catheter obstruction - 6 percent",
"     </li>",
"     <li>",
"      Hemorrhage (eg, pulmonary, pericardial, retroperitoneal) - 1 percent",
"     </li>",
"     <li>",
"      Plasma-related complications (eg, hypotension, anaphylaxis, serum sickness, hypoxia) &ndash; 7 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A continuous decline in complications was observed over the 15-year period of observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/80\">",
"     80",
"    </a>",
"    ]. As compared with patients presenting at earlier time points, patients treated from 2008 to 2011 had the following improved outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Less treatment-related mortality. There were no deaths from 2008 to 2011, compared with seven deaths from 1998 to 2008.",
"     </li>",
"     <li>",
"      Fewer catheter-related complications (27 versus 15 percent).",
"     </li>",
"     <li>",
"      Fewer major complications in patients with ADAMTS13 activity &lt;10 percent.",
"     </li>",
"     <li>",
"      No change in plasma-related complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This decline in catheter-related complications likely reflects a reduction in the mean number of days of plasma exchange for patients with ADAMTS13 activity &lt;10 percent, due to the use of more aggressive immunosuppression (eg, glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) and stopping plasma exchange abruptly following platelet count normalization rather than tapering the plasma exchange. Additional factors that may have contributed to the reduction in complications in all patients include the use of ultrasound guidance for central venous catheter insertion and enhanced prevention of nosocomial infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=see_link&amp;anchor=H79681696#H79681696\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\", section on 'Ultrasound guidance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large platelet losses, up to 71 percent of the total circulating platelet number, can occur following plasmapheresis performed for any reason [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/81\">",
"     81",
"    </a>",
"    ]. Losses appear to be related to the patient's disease (eg, greater losses in patients with hyperviscosity) and the type of instrument used. The importance of this observation for patients with TTP-HUS was emphasized by an accompanying case report in which the plasma exchange procedure itself caused persistent mild thrombocytopenia that was inappropriately considered to be ongoing active disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     POORLY RESPONSIVE, RESISTANT, OR RELAPSING DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ten to 20 percent of patients will have a transient, incomplete, or no response to plasma exchange therapy. At present, it is not possible to reliably identify these patients in advance.",
"   </p>",
"   <p>",
"    A preliminary report in a small number of patients suggests that patients with the clinical diagnosis of TTP-HUS who have moderate deficiencies of ADAMTS13 (ie, &gt;10 percent activity) without demonstrable anti-ADAMTS13 antibodies may be more likely to have resistant disease (4 of 4 versus only 2 of 13 with &lt;10 percent activity plus presence of the inhibitor) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/82\">",
"     82",
"    </a>",
"    ], whereas those with severe deficiencies are more likely to develop disease relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/44,83\">",
"     44,83",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13594423\">",
"     'Measurement of ADAMTS13 activity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If there is confidence that the diagnosis is indeed idiopathic TTP-HUS, the most reasonable option for those with poorly responsive or resistant disease is the addition of other modalities (eg, glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) if not previously employed, as described in the following section. Also, increasing the \"dose\" of plasma exchange to twice daily exchanges may be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/1,77\">",
"     1,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic TTP-HUS appears to be an autoimmune disorder; an increasing number of reports indicate success in patients with poorly responsive disease following the use of immunosuppressive agents (eg, glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/84-88\">",
"     84-88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not tested in a randomized setting,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (125 mg IV twice daily) may be a useful adjunct in patients with idiopathic TTP-HUS. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Immunosuppression'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a cohort of 12 patients with idiopathic TTP-HUS, six of whom had previous episodes, remission was attained in 10 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally) plus plasma exchange. However, this did not prevent relapse, as six of the 10 developed disease exacerbation in the first 30 days after discontinuing plasma exchange and the tapering of prednisone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An empirical regimen, adapted from the management of patients with systemic lupus erythematosus who have severe flares of activity, is the use of very high pulse doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , such as 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three days. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link&amp;anchor=H14#H14\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoid therapy offers unclear benefits in patients with TTP-HUS and HIV infection because of the high potential for side effects and accelerated immunosuppression. Its use in patients with HIV infection is indicated only if ADAMTS13 deficiency, caused by a high titer of anti-ADAMTS13 antibody, has been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a more severe course and more neurologic abnormalities who either do not respond to plasma exchange, develop worsening disease in spite of continuing plasma exchange plus glucocorticoids, or have relapsing disease, may benefit from more intensive immunosuppressive treatment.",
"   </p>",
"   <p>",
"    A number of case reports and reviews have indicated success employing the anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , in patients with primary refractory or relapsing TTP, with decrease or disappearance of the inhibitor to ADAMTS13, along with improvement of ADAMTS13 levels in some responders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15,87,90-99\">",
"     15,87,90-99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two systematic reviews of the available literature, benefit from the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      was described in 93 percent, with similar degrees of efficacy in both refractory and relapsed subjects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/100,101\">",
"       100,101",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the largest series reported to date, all 25 patients with acute",
"      <span class=\"nowrap\">",
"       refractory/relapsing",
"      </span>",
"      idiopathic TTP attained complete clinical and laboratory remission in a median of 11 days after initiating",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV once per week for a minimum of four doses, with each dose given immediately following plasma exchange) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/91\">",
"       91",
"      </a>",
"      ]. Treatment beyond four doses, to a maximum of eight, was needed in four patients who continued to have reduced ADAMTS13 activity or persistent IgG anti-ADAMTS13 antibodies.",
"      <br/>",
"      <br/>",
"      ADAMTS13 activity became normal following this treatment in 21 of 25 patients. Inhibitors of ADAMTS13 were present prior to rituximab treatment in 24 patients and became unmeasurable in 23 following treatment. There were no infectious complications, although one case of symptomatic strongyloides infection was detected after one dose of rituximab. At a median follow-up of 10 months, none of the cases has clinically relapsed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    can be administered during a course of plasma exchange. The dose of rituximab should be given immediately after the apheresis procedure to avoid unnecessary removal of the antibody. Although plasmapheresis removes much of the rituximab, plasma exchange on the day following rituximab treatment does not appear to impair rituximab&rsquo;s effectiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/102\">",
"     102",
"    </a>",
"    ]. This may be because the standard rituximab dose used (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    may exceed the dose required to deplete autoantibody-producing B cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized trials evaluating the benefit of combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    with plasma exchange. However, observational studies have suggested good outcomes in some settings. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter phase II trial (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=NCT00937131\">",
"       NCT00937131",
"      </a>",
"      ) evaluated the use of plasma exchange, glucocorticoids (1 g",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      intravenously daily for the first three days), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      intravenously within the first three days of admission and diagnosis, repeated weekly for four doses) in 40 patients with TTP (34 de novo and six in relapse) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/103\">",
"       103",
"      </a>",
"      ]. Results were compared with 40 previously untreated patients with TTP who did not receive rituximab during hospital admission. Major results included the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Of the 40 subjects treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      there were 37 survivors. No relapses occurred during the 12 months after initial presentation. Four relapses occurred in this group at 17, 25, 28, and 31 months, for a relapse rate of 10 percent.",
"     </li>",
"     <li>",
"      Of the 40 historical controls, there were 38 survivors. Twenty-one of the 38 had an acute TTP relapse at a median follow-up of 18 months, for a relapse rate of 57 percent. However, the selection and duration of follow-up of the historical control group is not clearly described and the frequency of relapse in this group of historical controls is much greater than other reports of consecutive, unselected patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15\">",
"       15",
"      </a>",
"      ]. Therefore, there may be some uncertainty about the magnitude of the benefit of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in this study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There was no difference in the median number of plasma exchanges required to achieve remission between the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and control groups (16.5 versus 18, respectively).",
"     </li>",
"     <li>",
"      No increase in infections was documented during the first year of follow-up in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      -treated group.",
"      <br/>",
"      <br/>",
"      This trial provides a rationale for the use of rituximab in patients who do not respond promptly to plasma exchange and steroids, or who have a relapse. Such patients almost always have severe ADAMTS13 deficiency and a demonstrable inhibitor, which provides a rationale for the use of rituximab.&nbsp;However, this rationale is not often present during their first episode, as information concerning ADAMTS13 activity is generally not available at the time plasma exchange is instituted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A multi-institutional randomized phase III clinical trial (The STAR Study: plasma exchange plus glucocorticoids with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=NCT00799773\">",
"     NCT00799773",
"    </a>",
"    ), designed to assess the efficacy of rituximab in diminishing the requirement for plasma exchange",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the frequency of exacerbations and relapses, was terminated due to poor accrual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/100,104,105\">",
"     100,104,105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    (CSA) has generally not been used in TTP-HUS because it can induce endothelial damage and cause a TTP-like picture on its own. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H112795998#H112795998\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Immunosuppressive agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some studies have indicated a beneficial effect of CSA in relapsed or resistant TTP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/84,89,106-108\">",
"     84,89,106-108",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a patient who failed therapy with plasmapheresis and antiplatelet agents, CSA (300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      orally) induced remission within eight days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/84\">",
"       84",
"      </a>",
"      ]. The patient relapsed three months after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      was discontinued, and again rapidly remitted with the reinstitution of therapy.",
"     </li>",
"     <li>",
"      In a report of three patients with early recurrent TTP, CSA induced durable remissions that were associated with recovery of ADAMTS13 activity and disappearance of inhibitors of ADAMTS13 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort of eight patients with previous episodes of TTP, remission was attained in all eight following treatment with CSA, with no subsequent exacerbations or recurrences in the first 30 days after discontinuing plasma exchange [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    may be effective in some patients with TTP who do not achieve durable remissions with plasma exchange and corticosteroids. While there is currently more experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in this setting, cyclosporine may be considered as adjunctive treatment in patients responding poorly to rituximab. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Rituximab'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Other immunosupressives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two other modalities that may be effective are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/109-111\">",
"     109-111",
"    </a>",
"    ] and intravenous immune globulin (IVIG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/112\">",
"     112",
"    </a>",
"    ]. However, these agents are not an alternative to continuing plasma exchange. The mechanism by which IVIG might act is not well understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/112\">",
"     112",
"    </a>",
"    ]. An IgG may be provided that binds to and inactivates a platelet aggregating protein, although there are no data to support this possibility. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Treatment of concomitant infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTP-HUS that is apparently refractory to therapy or associated with exacerbations may be associated with bacterial infection, either occult or overt, which may either mimic TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/113\">",
"     113",
"    </a>",
"    ] or trigger the occurrence of an acute episode of TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/114-118\">",
"     114-118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of two cases, TTP-HUS recurred in one patient in association with the discontinuation of antimicrobial therapy, while another had a sustained remission only after successful treatment of a dental abscess [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/115\">",
"       115",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second report, two patients with TTP-HUS who had apparently relapsed during treatment had documented systemic infection with Staphylococcus aureus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/116\">",
"       116",
"      </a>",
"      ]. Both responded to removal of their infected central venous catheters, institution of antibiotics, and continuation of plasma exchange.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral nephrectomy has been tried in four women with unremitting HUS (three required dialysis) who were unresponsive to intensive plasma exchange and who had severe neurologic disease (two had seizures and coma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/119\">",
"     119",
"    </a>",
"    ]. Within two weeks after nephrectomy, the platelet count normalized and the disease was thought to be in complete remission. One additional case has been reported with benefit in a woman with severe systemic lupus erythematosus and TTP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/120\">",
"     120",
"    </a>",
"    ]. The mechanism of benefit from nephrectomy is not clear and bilateral nephrectomy should only be considered as a last resort.",
"   </p>",
"   <p>",
"    Splenectomy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and antiplatelet agents have been tried in refractory patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/88,121\">",
"     88,121",
"    </a>",
"    ]. These modalities were commonly used with no success in the era prior to the use of plasma exchange [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/11\">",
"     11",
"    </a>",
"    ]. There appears to be little or no benefit to splenectomy unless accompanied by the use of corticosteroids and further plasma exchange [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/21,23,122\">",
"     21,23,122",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10315058\">",
"     'Ineffective initial treatments'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Long-term follow-up",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87027452\">",
"    <span class=\"h3\">",
"     Laboratory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;After discontinuation of plasma exchange, patients should be frequently monitored with complete blood counts and serum lactate dehydrogenase (LDH) concentrations. If the tests remain normal, the interval between observations can be lengthened, but not discontinued.",
"   </p>",
"   <p>",
"    Relapses, defined as recurrent TTP-HUS after at least 30 days of no treatment and no evidence of TTP-HUS, can occur in patients with severe ADAMTS13 deficiency who respond to the initial course of therapy. Relapses usually occur within the first year, but occasionally are seen as late as 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15,23,123,124\">",
"     15,23,123,124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of relapses after complete remission has been addressed in a follow-up study from the Canadian Apheresis Trial. Among 63 patients followed for up to 10 years, the estimated 10-year relapse rate was 36 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/122\">",
"       122",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The estimated frequency of relapse among patients in the Oklahoma TTP-HUS registry at 7.5 years was 41 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is therefore recommended that patients be monitored indefinitely for recurrence of the disease. The most important recommendation for patients who have recovered from TTP-HUS is that they must report to their physician immediately upon the occurrence of any systemic symptoms. Their evaluation must include a complete blood count to determine if a relapsed episode of TTP-HUS has occurred.",
"   </p>",
"   <p>",
"    In one study, serial measurements of ADAMTS13 activity and ADAMTS13 antibody were obtained in 24 TTP patients in remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/125\">",
"     125",
"    </a>",
"    ]. During an average of 23 months of follow-up, there were nine episodes of TTP relapse among six patients. Lower ADAMTS13 activity and younger age were significantly associated with a higher risk of relapse in the three months after the specimen was taken, while ADAMTS13 antibody IgG levels were not predictive of relapse.",
"   </p>",
"   <p>",
"    However, it is not yet clear if serial measurements of ADAMTS13 activity during clinical remission can accurately predict relapse",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serve as an indication for the use of immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15,90\">",
"     15,90",
"    </a>",
"    ]. We do not recommend ADAMTS13 measurements during clinical remission outside of a clinical trial because the occurrence of severe deficiency during remission is common and the clinical importance of this observation is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no known effective maintenance therapy for the prevention of relapses in idiopathic TTP-HUS. However, prophylactic treatment with small volumes of fresh frozen plasma (eg, 10 to 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    every two to four weeks) is effective in patients with",
"    <strong>",
"     congenital",
"    </strong>",
"    TTP who have disease progression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frequent relapses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/2,126-129\">",
"     2,126-129",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10314900\">",
"     'Congenital TTP'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An uncontrolled study of six patients with one or more relapses with TTP suggested that splenectomy performed during hematologic remission might be beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/130\">",
"     130",
"    </a>",
"    ]. The relapse rate fell from 2.3 to 0.1 relapses per year during an average follow-up of almost four years after surgery. This small study requires further validation.",
"   </p>",
"   <p>",
"    Immunosuppressive agents have typically been used to induce remissions and to treat relapse, rather than as maintenance therapy. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Immunosuppressive agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1991593\">",
"    <span class=\"h1\">",
"     SPECIAL SCENARIOS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTP-HUS occurring during pregnancy had a maternal and fetal mortality of approximately 90 percent prior to the use of plasma exchange [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/131\">",
"     131",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/56/38793?source=see_link\">",
"     \"Thrombocytopenia in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite pheresis-induced removal of pregnancy-maintaining hormones, plasma exchange is the treatment of choice for TTP-HUS occurring during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]. In addition to plasma exchange, delivery should be induced if the disease is severe and the fetus is viable, since this will resolve preeclampsia and the HELLP syndrome, which may be difficult to distinguish from TTP-HUS.",
"   </p>",
"   <p>",
"    Although delivery does not generally cause resolution of TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/134\">",
"     134",
"    </a>",
"    ], there is anecdotal evidence that it may do so in selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/135\">",
"     135",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17897?source=see_link&amp;anchor=H7#H7\">",
"     \"HELLP syndrome\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, termination of the pregnancy is usually not necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/11,23,133,136\">",
"     11,23,133,136",
"    </a>",
"    ]. In one series of 108 patients, nine women who were pregnant were in their third trimester at the time of initial presentation of TTP-HUS; all successfully completed their pregnancies, with delivery of 10 infants who remained healthy throughout two months of observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been no report of transmission of TTP to the infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/23,133,136\">",
"     23,133,136",
"    </a>",
"    ]. However, intrauterine fetal death may occur due to placental infarction caused by thrombosis of the decidual arterioles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Relapse in subsequent pregnancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although available data are observational and on few patients, subsequent pregnancies after recovery from TTP-HUS may carry a risk for disease relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/135,136,138,139\">",
"     135,136,138,139",
"    </a>",
"    ]. It has been observed in several patients that the finding of severe ADAMTS13 deficiency with a demonstrable inhibitor during pregnancy may predict a risk for TTP relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/139,140\">",
"     139,140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, five women suffered eight relapses during 16 pregnancies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/136\">",
"       136",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A report from the Oklahoma TTP-HUS Registry of 19 consecutive women with 30 pregnancies following recovery from TTP-HUS suggested a lower risk of relapse. Five of the 19 women had one relapse each, diagnosed during a subsequent pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/141\">",
"       141",
"      </a>",
"      ]. However, in two of these women severe preeclampsia, rather than TTP-HUS, may have been the more accurate diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/141\">",
"       141",
"      </a>",
"      ]. We have followed nine women whose initial episodes of TTP were associated with severe ADAMTS13 deficiency, and who have had 16 subsequent pregnancies. ADAMTS13 activity was not measured during these pregnancies. Only two of the 16 pregnancies were associated with recurrent TTP; in these patients, TTP recurred 9 and 30 days after uncomplicated deliveries of healthy infants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lower risk of relapse in this series was probably the result of the complete follow-up of all patients that included documentation of all uncomplicated pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/141\">",
"     141",
"    </a>",
"    ]. Previous case reports and small series probably focused only on women with complicated pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12755683\">",
"    <span class=\"h3\">",
"     Follow-up during subsequent pregnancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who become pregnant following recovery from TTP must be followed closely, preferably by an obstetrician with experience in high-risk pregnancies. They should be questioned carefully about the presence of symptoms that could suggest recurrent TTP (eg, petechial rash, neurologic symptoms, symptomatic anemia, fever). A complete blood count, including platelet count, should be obtained at each prenatal visit.",
"   </p>",
"   <p>",
"    The certain risks of severe complications from plasma exchange [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/17\">",
"     17",
"    </a>",
"    ] may exceed any potential benefit of prophylactic treatment during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10315756\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients may present with a thrombotic microangiopathy due to concurrent infection or HIV-associated nephropathy, which can be confused with TTP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/142\">",
"     142",
"    </a>",
"    ]. However, patients with HIV infection may have typical TTP, and should be treated with plasma exchange in addition to appropriate HIV treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H112794614#H112794614\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'HIV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Drug-induced TTP-HUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs have been associated with TTP-HUS, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , oral contraceptive, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H19#H19\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of plasma exchange therapy in such patients is unclear; the most important step is to discontinue the offending drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/75\">",
"     75",
"    </a>",
"    ]. Plasma exchange and use of immunosuppressive therapy appear to be ineffective with some drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Exceptions to the use of plasma exchange'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H17#H17\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Mitomycin C'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In two series consisting of 158 cases of TTP-HUS associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    , the mortality rate in patients receiving plasmapheresis was significantly lower than in those who did not undergo this procedure (24 versus 50 percent and 18 versus 57 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/143,144\">",
"     143,144",
"    </a>",
"    ]. However, some of these patients may have had severe ADAMTS13 deficiency unrelated to incidental ticlopidine ingestion.",
"   </p>",
"   <p>",
"    With certain other drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    , the disease has such an explosive onset that plasma exchange seems mandatory because the distinction from idiopathic TTP-HUS is not possible. Patients who have recovered from quinine-induced TTP-HUS must be warned that even the low concentrations of quinine in beverages, such as tonic water, can cause a recurrent, severe episode. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H21#H21\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Quinine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10314900\">",
"    <span class=\"h2\">",
"     Congenital TTP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with congenital TTP have low to absent levels of ADAMTS13 due to genetic mutations (ie, without an inhibitor). Thus, when treatment is required, plasma infusion alone, as a source of ADAMTS13, is effective. Plasma exchange is not necessary; therefore the risks of insertion and maintenance of a central venous catheter can be avoided. Recombinant ADAMTS13, when and if it becomes available, is likely to be effective treatment for congenital TTP by providing the missing enzyme without the accompanying volume load and risk for allergic reactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H12895661#H12895661\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Recombinant human ADAMTS13'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H8#H8\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'ADAMTS13 deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial treatment of acute attacks of congenital TTP with 10 to 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of fresh frozen plasma appears to be effective. This treatment can be continued approximately every two weeks in those with frequent episodes, progressive disease, or to avoid relapses at times of infection or other stress situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/2,126-129\">",
"     2,126-129",
"    </a>",
"    ]. However, ad hoc treatment schedules are preferable for those patients who remain asymptomatic for prolonged periods of time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1991633\">",
"    <span class=\"h2\">",
"     Atypical HUS in adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term atypical HUS had been used exclusively for children with thrombotic microangiopathy and acute renal failure without a preceding diarrheal illness. This term subsequently has been adopted by some clinicians to describe adults with thrombotic microangiopathy, acute kidney injury, no evidence of diarrheal illness or Shiga toxin-producing Escherichia coli infection, and ADAMTS13 activity &ge;10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/145-147\">",
"     145-147",
"    </a>",
"    ]. Some of these individuals have been found to have defects in the complement system that result in excessive complement activation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=see_link\">",
"     \"Atypical hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our approach to treatment for most adults with this clinical presentation is to initiate plasma exchange while awaiting testing for Shiga toxin producing E. coli and ADAMTS13 activity. Exceptions include those known to have a genetic form of atypical HUS who have responded to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    and those with a family history of HUS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=see_link&amp;anchor=H7#H7\">",
"     \"Atypical hemolytic uremic syndrome in children\", section on 'Genetic forms of HUS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We continue plasma exchange for those adults who show a benefit from this therapy, using parameters described for adults with idiopathic TTP-HUS. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Idiopathic TTP-HUS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A short course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/63/28662?source=see_link\">",
"       eculizumab",
"      </a>",
"      for adults who do not benefit from plasma exchange or for those in whom complement testing ultimately shows abnormalities consistent with abnormal complement activation has been employed by some physicians with occasional, anecdotal success. However, there is no evidence that apparent success in a single episode requires ongoing lifetime administration. (See",
"      <a class=\"local\" href=\"#H5534574\">",
"       'Eculizumab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal transplantation may be appropriate for some individuals for whom plasma exchange and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/63/28662?source=see_link\">",
"       eculizumab",
"      </a>",
"      are ineffective.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis and management of children with atypical HUS are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=see_link&amp;anchor=H15#H15\">",
"     \"Atypical hemolytic uremic syndrome in children\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780699\">",
"    <span class=\"h2\">",
"     Long-term follow-up",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780706\">",
"    <span class=\"h3\">",
"     Laboratory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;After discontinuation of plasma exchange, patients should be frequently monitored with complete blood counts and serum lactate dehydrogenase (LDH) concentrations. If the tests remain normal, the interval between observations can be lengthened, but not discontinued.",
"   </p>",
"   <p>",
"    Relapses, defined as recurrent TTP-HUS after at least 30 days of no treatment and no evidence of TTP-HUS, can occur in patients with severe ADAMTS13 deficiency who respond to the initial course of therapy. Relapses usually occur within the first year, but occasionally are seen as late as 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15,23,123,124\">",
"     15,23,123,124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of relapses after complete remission has been addressed in a follow-up study from the Canadian Apheresis Trial. Among 63 patients followed for up to 10 years, the estimated 10-year relapse rate was 36 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/122\">",
"       122",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The estimated frequency of relapse among patients in the Oklahoma TTP-HUS registry at 7.5 years was 41 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is therefore recommended that patients be monitored indefinitely for recurrence of the disease. The most important recommendation for patients who have recovered from TTP-HUS is that they must report to their physician immediately upon the occurrence of any systemic symptoms. Their evaluation must include a complete blood count to determine if a relapsed episode of TTP-HUS has occurred.",
"   </p>",
"   <p>",
"    It is not clear if serial measurements of ADAMTS13 activity during clinical remission can accurately predict relapse",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serve as an indication for the use of immunosuppressive therapy, and we do not measure ADAMTS13 activity during remission outside of a clinical trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15,90\">",
"     15,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, serial measurements of ADAMTS13 activity and ADAMTS13 antibody were obtained in 24 TTP patients in remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/125\">",
"     125",
"    </a>",
"    ]. During an average of 23 months of follow-up, there were nine episodes of TTP relapse among six patients. Lower ADAMTS13 activity and younger age were significantly associated with a higher risk of relapse in the three months after the specimen was taken, while ADAMTS13 antibody IgG levels were not predictive of relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22780713\">",
"    <span class=\"h3\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no known effective maintenance therapy for the prevention of relapses in idiopathic TTP-HUS. However, prophylactic treatment with small volumes of fresh frozen plasma (eg, 10 to 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    every two to four weeks) is effective in patients with",
"    <strong>",
"     congenital",
"    </strong>",
"    TTP who have disease progression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frequent relapses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/2,126-129\">",
"     2,126-129",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10314900\">",
"     'Congenital TTP'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An uncontrolled study of six patients with one or more relapses with TTP suggested that splenectomy performed during hematologic remission might be beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/130\">",
"     130",
"    </a>",
"    ]. The relapse rate fell from 2.3 to 0.1 relapses per year during an average follow-up of almost four years after surgery. This small study requires further validation.",
"   </p>",
"   <p>",
"    Immunosuppressive agents have typically been used to induce remissions and to treat relapse, rather than as maintenance therapy. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Immunosuppressive agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107006957\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107006964\">",
"    <span class=\"h2\">",
"     Scoring systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of scoring systems for assessing short-term mortality in patients with TTP-HUS have been devised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/13,148,149\">",
"     13,148,149",
"    </a>",
"    ]. These scoring systems are typically interpreted as correlating with severe acquired ADAMTS13 deficiency, but their clinical value for assisting management decisions for individual patients is uncertain. The value of scoring systems may be that they could allow comparison of patient groups in a clinical trial. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107006993\">",
"    <span class=\"h2\">",
"     Predicting initial response",
"    </span>",
"    &nbsp;&mdash;&nbsp;While severe ADAMTS13 deficiency (ie, &lt;10 percent of normal) and the presence of an inhibitor to ADAMTS13 are highly specific for the diagnosis of idiopathic TTP-HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/6,8\">",
"     6,8",
"    </a>",
"    ], the value of these observations in predicting initial response to treatment has been questioned:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 48 patients with idiopathic TTP-HUS, many of the patients appeared to respond to treatment with plasma exchange, despite ADAMTS13 activity ranging from &lt;5 to &gt;25 percent of normal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There have been reports of patients with acquired autoimmune ADAMTS13 deficiency who have achieved complete clinical remission in spite of continued absence of ADAMTS13 activity, the continued presence of an inhibitor,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the presence of ultralarge VWF multimers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15,34,90,109,150\">",
"       15,34,90,109,150",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107007000\">",
"    <span class=\"h2\">",
"     Predicting risk of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies suggest that severe ADAMTS13 deficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of an inhibitor may have prognostic, as well as diagnostic, value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/91,125,151\">",
"     91,125,151",
"    </a>",
"    ]. Documentation of severe ADAMTS13 deficiency at the time of a patient's presentation predicts for a risk for relapse over the following 7.5 years of 41 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15,109\">",
"     15,109",
"    </a>",
"    ]; conversely, relapse is rare in patients who do not have severe ADAMTS13 deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of 35 adult patients with a first episode of thrombotic microangiopathy, an undetectable level of ADAMTS13, and no other obvious medical cause suggested that undetectable ADAMTS13 activity during remission predicted a risk for relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/151\">",
"       151",
"      </a>",
"      ]. At remission, ADAMTS13 activity increased to levels &gt;15 percent in 19 of the 32 patients (59 percent), and remained undetectable (ie, &lt;5 percent of normal activity) in the remaining 41 percent. The relapse rates over the subsequent 18 months were 5 and 38 percent, respectively.",
"     </li>",
"     <li>",
"      However, another study of 41 patients with severe ADAMTS13 deficiency who survived their initial acute episode of TTP-HUS did not demonstrate an increased risk for relapse among patients with persistent severe ADAMTS13 deficiency during remission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of severely reduced ADAMTS13 activity, along with an inhibitor to ADAMTS13, may be associated with a worse overall clinical outcome, including delayed platelet count recovery, a need for more intensive treatment, as well as a higher risk for relapsing disease and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15,44,83\">",
"     15,44,83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107007014\">",
"    <span class=\"h2\">",
"     Long-term outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients report that they have not recovered their previous physical stamina and cognitive ability following recovery from TTP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/152,153\">",
"     152,153",
"    </a>",
"    ]. Defects in such functions as memory, attention, concentration, visual learning, and psychomotor function, as well as reduced endurance have been described, and did not appear to improve when serial assessments were performed up to five years following treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/154-156\">",
"     154-156",
"    </a>",
"    ]. Many of these defects are characteristic of disorders associated with diffuse subcortical microvascular disease, a conclusion that was supported by the finding of small vessel ischemic changes in 9 of 23 MRI examinations in a group of 27 patients with a history of idiopathic TTP who were functioning normally in their activities of daily living [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/156\">",
"     156",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may also have difficulty because of the unfamiliarity of TTP-HUS to their families and even their primary care physicians. They have appreciated the availability of a support group and newsletters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/152,153\">",
"     152,153",
"    </a>",
"    ]. The latter are available on a website maintained and updated by Dr. James N. George:",
"    <a class=\"external\" href=\"file://www.ouhsc.edu/platelets\">",
"     www.ouhsc.edu/platelets",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Chronic kidney disease, as defined by a creatinine clearance &lt;60",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    is common in patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    -induced TTP-HUS but may not occur in patients with TTP-HUS associated with severe ADAMTS13 deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/157\">",
"     157",
"    </a>",
"    ]. The renal prognosis of HUS due to enterohemorrhagic E. coli infection is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\", section on 'Hemolytic-uremic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The morbidity and mortality of relapsed TTP-HUS is less than with the initial episode for two reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/31/42490/abstract/158,159\">",
"     158,159",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There is less delay in diagnosis, as is common with initial episodes.",
"     </li>",
"     <li>",
"      Patients who have responded once to plasma exchange treatment will respond again.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) should be suspected in a patient who presents with microangiopathic hemolytic anemia (MAHA) (",
"      <a class=\"graphic graphic_picture graphicRef70851 \" href=\"mobipreview.htm?37/50/38694\">",
"       picture 1",
"      </a>",
"      ) and thrombocytopenia without an apparent alternative etiology.",
"     </li>",
"     <li>",
"      Idiopathic TTP-HUS is a",
"      <strong>",
"       medical emergency",
"      </strong>",
"      that is almost always fatal if appropriate treatment is not initiated promptly. Accordingly, all patients suspected of having idiopathic TTP-HUS should be admitted without delay to a medical center capable of performing plasma exchange and treated on an urgent basis with plasma exchange, rather than with plasma infusion or the use of immunosuppressive agents alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Plasma exchange should be initially performed daily until the platelet count has normalized and hemolysis largely ceased, as evidenced by a return of the serum lactate dehydrogenase (LDH) concentration to normal or near normal (",
"      <a class=\"graphic graphic_algorithm graphicRef69258 \" href=\"mobipreview.htm?4/62/5088\">",
"       algorithm 1",
"      </a>",
"      ). Plasma exchange may be discontinued in patients found to have an ADAMTS13 activity &ge;10 percent if the patient&rsquo;s clinical presentation and course suggest an etiology other than severe acquired ADAMTS13 deficiency, and where plasma exchange therapy would not be potentially beneficial. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Daily exchange'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If plasma exchange is not immediately available, plasma infusion may serve as",
"      <strong>",
"       temporary",
"      </strong>",
"      treatment until the patient can be transferred to a medical center capable of performing plasma exchange. (See",
"      <a class=\"local\" href=\"#H13594392\">",
"       'Plasma exchange versus plasma infusion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The appropriate treatment of adults with typical (ie, post-diarrheal) HUS due to Shiga toxin-producing E. coli is unresolved. Plasma exchange treatment may be appropriate for adults at the time of presentation for the following reasons:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The presence of Shiga toxin-producing E. coli may be uncertain at the time of presentation.",
"     </li>",
"     <li>",
"      TTP-HUS associated severely reduced ADAMTS13 activity may present with diarrhea, including overtly bloody diarrhea.",
"     </li>",
"     <li>",
"      Shiga toxin-associated HUS is much less common among adults than in young children.",
"     </li>",
"     <li>",
"      Severe antibody-mediated ADAMTS13 deficiency is much more common among adults than in children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of typical (post-diarrheal) HUS in children is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30649?source=see_link\">",
"       \"Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest the use of adjunctive treatment with glucocorticoids in any of the following settings (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H32\">",
"       'Glucocorticoids'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If there is no evidence for a drug-induced etiology or a bloody diarrheal prodrome, or severe renal failure.",
"     </li>",
"     <li>",
"      In patients whose platelet counts do not increase within several days of treatment with plasma exchange.",
"     </li>",
"     <li>",
"      In those in whom thrombocytopenia recurs when plasma exchange treatments are diminished or discontinued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with refractory or recurrent TTP-HUS (ie, who have a severe course, do not rapidly respond to plasma exchange, worsen with neurologic abnormalities despite plasma exchange plus corticosteroids, or have relapsing disease):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Cyclosporin has also been used in this setting. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Immunosuppressive agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest increasing plasma exchange frequency to twice daily (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Twice-daily exchange'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is important to determine if TTP-HUS is associated with another medical condition that could affect its management. (See",
"      <a class=\"local\" href=\"#H1991593\">",
"       'Special scenarios'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pregnancy-associated TTP-HUS typically responds to plasma exchange. (See",
"      <a class=\"local\" href=\"#H41\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected individuals can develop thrombotic microangiopathy due to HIV associated nephropathy or to idiopathic TTP-HUS. The latter responds to plasma exchange. (See",
"      <a class=\"local\" href=\"#H10315756\">",
"       'HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a drug-induced etiology is suspected for a sudden onset of MAHA, thrombocytopenia, and acute kidney injury, plasma exchange is often initiated because a drug-induced etiology cannot be known with confidence. For patients with the insidious onset of renal failure associated with MAHA and thrombocytopenia, plasma exchange may be ineffective. (See",
"      <a class=\"local\" href=\"#H43\">",
"       'Drug-induced TTP-HUS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital TTP (ie, a genetic defect that impairs ADAMTS13 production) can be treated with plasma infusion rather than plasma exchange. (See",
"      <a class=\"local\" href=\"#H10314900\">",
"       'Congenital TTP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adults with",
"      <strong>",
"       atypical",
"      </strong>",
"      HUS (ie, thrombotic microangiopathy, acute renal injury, and ADAMTS13 activity &ge;10 percent) may respond to plasma exchange",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/63/28662?source=see_link\">",
"       eculizumab",
"      </a>",
"      therapy. (See",
"      <a class=\"local\" href=\"#H1991633\">",
"       'Atypical HUS in adults'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While the mortality of TTP-HUS has improved dramatically with plasma exchange and many patients recover completely, residual renal and neurologic deficits can occur in some patients. It is not clear that serial measurements of ADAMTS13 activity predict initial response to plasma exchange or disease relapse. (See",
"      <a class=\"local\" href=\"#H107006957\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/1\">",
"      George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010; 116:4060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/2\">",
"      Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/3\">",
"      Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int 1987; 32:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/4\">",
"      Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001; 60:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/5\">",
"      Allford SL, Hunt BJ, Rose P, et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/6\">",
"      Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003; 14:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/7\">",
"      Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/8\">",
"      Vesely SK, George JN, L&auml;mmle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/9\">",
"      Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/10\">",
"      Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/11\">",
"      Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature. Medicine (Baltimore) 1966; 45:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/12\">",
"      von Baeyer H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 2002; 6:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/13\">",
"      Wyllie BF, Garg AX, Macnab J, et al. Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange. Br J Haematol 2006; 132:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/14\">",
"      Michael M, Elliott EJ, Ridley GF, et al. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev 2009; :CD003595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/15\">",
"      Kremer Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/16\">",
"      Rizvi MA, Vesely SK, George JN, et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion 2000; 40:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/17\">",
"      Nguyen L, Terrell DR, Duvall D, et al. Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008. Transfusion 2009; 49:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/18\">",
"      Karpac CA, Li X, Terrell DR, et al. Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haematol 2008; 141:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/19\">",
"      Robertson MD, Zumberg M. Post-appendectomy thrombotic thrombocytopenic purpura: a case report and review of the literature. Am J Hematol 2007; 82:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/20\">",
"      Swisher KK, Doan JT, Vesely SK, et al. Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica 2007; 92:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/21\">",
"      Thompson CE, Damon LE, Ries CA, Linker CA. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood 1992; 80:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/22\">",
"      Byrnes JJ, Moake JL, Klug P, Periman P. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol 1990; 34:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/23\">",
"      Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991; 325:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/24\">",
"      Rock GA. Management of thrombotic thrombocytopenic purpura. Br J Haematol 2000; 109:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/25\">",
"      Kaplan AA. Therapeutic apheresis for cancer related hemolytic uremic syndrome. Ther Apher 2000; 4:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/26\">",
"      Bueno D Jr, Sevigny J, Kaplan AA. Extracorporeal treatment of thrombotic microangiopathy: a ten year experience. Ther Apher 1999; 3:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/27\">",
"      Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/28\">",
"      Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/29\">",
"      Novitzky N, Jacobs P, Rosenstrauch W. The treatment of thrombotic thrombocytopenic purpura: plasma infusion or exchange? Br J Haematol 1994; 87:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/30\">",
"      Pene F, Vigneau C, Auburtin M, et al. Outcome of severe adult thrombotic microangiopathies in the intensive care unit. Intensive Care Med 2005; 31:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/31\">",
"      Coppo P, Bussel A, Charrier S, et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) 2003; 82:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/32\">",
"      Novitzky N, Thomson J, Abrahams L, et al. Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy. Br J Haematol 2005; 128:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/33\">",
"      George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/34\">",
"      Tsai HM, Raoufi M, Zhou W, et al. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2006; 95:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/35\">",
"      Dundas S, Murphy J, Soutar RL, et al. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 1999; 354:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/36\">",
"      Menne J, Nitschke M, Stingele R, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012; 345:e4565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/37\">",
"      Colic E, Dieperink H, Titlestad K, Tepel M. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet 2011; 378:1089.",
"     </a>",
"    </li>",
"    <li>",
"     file://soliris.net/sites/default/files/assets/soliris_pi.pdf (Accessed on February 20, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/39\">",
"      Greinacher A, Friesecke S, Abel P, et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011; 378:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/40\">",
"      George JN, Li X, McMinn JR, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004; 44:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/41\">",
"      Palmisano J, Agraharkar M, Kaplan AA. Successful treatment of cisplatin-induced hemolytic uremic syndrome with therapeutic plasma exchange. Am J Kidney Dis 1998; 32:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/42\">",
"      Choi MK, Hong JY, Jang JH, Lim HY. TTP-HUS associated with sunitinib. Cancer Res Treat 2008; 40:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/43\">",
"      George JN. Hematopoietic stem cell transplantation-associated thrombotic microangiopathy: defining a disorder. Bone Marrow Transplant 2008; 41:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/44\">",
"      Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103:4043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/45\">",
"      Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2004; :407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/46\">",
"      Harkness DR, Byrnes JJ, Lian EC, et al. Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA 1981; 246:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/47\">",
"      Lind SE. Thrombocytopenic purpura and platelet transfusion. Ann Intern Med 1987; 106:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/48\">",
"      Swisher KK, Terrell DR, Vesely SK, et al. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion 2009; 49:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/49\">",
"      Rosove MH, Ho WG, Goldfinger D. Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura. Ann Intern Med 1982; 96:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/50\">",
"      Mintz PD, Neff A, MacKenzie M, et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006; 46:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/51\">",
"      Rock G, Yousef H, Neurath D, Lu M. ADAMTS-13 in fresh, stored, and solvent/detergent-treated plasma. Transfusion 2006; 46:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/52\">",
"      Scott EA, Puca KE, Pietz BC, et al. Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion 2007; 47:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/53\">",
"      Apter AJ, Kaplan AA. An approach to immunologic reactions associated with plasma exchange. J Allergy Clin Immunol 1992; 90:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/54\">",
"      Blackall DP, Uhl L, Spitalnik SL, Transfusion Practices Committee. Cryoprecipitate-reduced plasma:rationale for use and efficacy in the treatment of thrombotic thrombocytopenic purpura. Transfusion 2001; 41:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/55\">",
"      Rock G, Shumak KH, Sutton DM, et al. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol 1996; 94:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/56\">",
"      Raife TJ, Friedman KD, Dwyre DM. The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasma. Transfusion 2006; 46:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/57\">",
"      Zeigler ZR, Shadduck RK, Gryn JF, et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher 2001; 16:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/58\">",
"      Rock G, Anderson D, Clark W, et al. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 2005; 129:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/59\">",
"      Moake J, Chintagumpala M, Turner N, et al. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 1994; 84:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/60\">",
"      Horowitz MS, Pehta JC. SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang 1998; 74 Suppl 1:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/61\">",
"      Evans G, Llewelyn C, Luddington R, et al. Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura. Clin Lab Haematol 1999; 21:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/62\">",
"      Harrison CN, Lawrie AS, Iqbal A, et al. Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol 1996; 94:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/63\">",
"      Pehta JC. Clinical studies with solvent detergent-treated products. Transfus Med Rev 1996; 10:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/64\">",
"      Flamholz R, Jeon HR, Baron JM, Baron BW. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses? J Clin Apher 2000; 15:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/65\">",
"      Yarranton H, Cohen H, Pavord SR, et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 2003; 121:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/66\">",
"      de la Rubia J, Arriaga F, Linares D, et al. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2001; 114:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/67\">",
"      Alvarez-Larr&aacute;n A, Del R&iacute;o J, Ram&iacute;rez C, et al. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004; 86:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/68\">",
"      del R&iacute;o-Garma J, Alvarez-Larr&aacute;n A, Mart&iacute;nez C, et al. Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. Br J Haematol 2008; 143:39.",
"     </a>",
"    </li>",
"    <li>",
"     Taft EG. Advances in the treatment of TTP. In: Apheresis, Rock G (Ed), Wiley Liss, New York 1990. p.151.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/70\">",
"      George JN, Gilcher RO, Smith JW, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: diagnosis and management. J Clin Apher 1998; 13:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/71\">",
"      Conlon PJ, Howell DN, Macik G, et al. The renal manifestations and outcome of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in adults. Nephrol Dial Transplant 1995; 10:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/72\">",
"      Morel-Maroger L, Kanfer A, Solez K, et al. Prognostic importance of vascular lesions in acute renal failure with microangiopathic hemolytic anemia (hemolytic-uremic syndrome): clinicopathologic study in 20 adults. Kidney Int 1979; 15:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/73\">",
"      Hayslett JP. Current concepts. Postpartum renal failure. N Engl J Med 1985; 312:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/74\">",
"      Walfe JA, McCann RL, Sanfilippo F. Cyclosporine-associated microangiopathy in renal transplantation: a severe but potentially reversible form of early graft injury. Transplantation 1986; 41:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/75\">",
"      Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. Kidney Int 1995; 48:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/76\">",
"      George JN, Vesely SK, Terrell DR. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004; 41:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/77\">",
"      Nguyen L, Li X, Duvall D, et al. Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion 2008; 48:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/78\">",
"      McMinn JR Jr, Thomas IA, Terrell DR, et al. Complications of plasma exchange in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a study of 78 additional patients. Transfusion 2003; 43:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/79\">",
"      Howard MA, Williams LA, Terrell DR, et al. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2006; 46:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/80\">",
"      Som S, Deford CC, Kaiser ML, et al. Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion 2012; 52:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/81\">",
"      Perdue JJ, Chandler LK, Vesely SK, et al. Unintentional platelet removal by plasmapheresis. J Clin Apher 2001; 16:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/82\">",
"      Mori Y, Wada H, Gabazza EC, et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 2002; 42:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/83\">",
"      Coppo P, Wolf M, Veyradier A, et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 2006; 132:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/84\">",
"      Kierdorf H, Maurin N, Heintz B. Cyclosporine for thrombotic thrombocytopenic purpura. Ann Intern Med 1993; 118:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/85\">",
"      Pasquale D, Vidhya R, DaSilva K, et al. Chronic relapsing thrombotic thrombocytopenic purpura: role of therapy with cyclosporine. Am J Hematol 1998; 57:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/86\">",
"      Allan DS, Kovacs MJ, Clark WF. Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. Haematologica 2001; 86:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/87\">",
"      George JN. Controlling chronic TTP (editorial). Blood 2005; 106:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/88\">",
"      Beloncle F, Buffet M, Coindre JP, et al. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion 2012; 52:2436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/89\">",
"      Cataland SR, Jin M, Ferketich AK, et al. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2007; 136:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/90\">",
"      Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005; 106:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/91\">",
"      Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007; 136:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/92\">",
"      Zheng X, Pallera AM, Goodnough LT, et al. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003; 138:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/93\">",
"      Yomtovian R, Niklinski W, Silver B, et al. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004; 124:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/94\">",
"      Ahmad A, Aggarwal A, Sharma D, et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 2004; 77:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/95\">",
"      Galbusera M, Bresin E, Noris M, et al. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood 2005; 106:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/96\">",
"      Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008; 141:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/97\">",
"      Jasti S, Coyle T, Gentile T, et al. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher 2008; 23:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/98\">",
"      Froissart A, Buffet M, Veyradier A, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 2012; 40:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/99\">",
"      Bhagirath VC, Kelton JG, Moore J, Arnold DM. Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura. Transfusion 2012; 52:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/100\">",
"      George JN, Woodson RD, Kiss JE, et al. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 2006; 21:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/101\">",
"      Caramazza D, Quintini G, Abbene I, et al. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. Transfusion 2010; 50:2753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/102\">",
"      McDonald V, Manns K, Mackie IJ, et al. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/103\">",
"      Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/104\">",
"      Kiss JE. Randomized clinical trials in thrombotic thrombocytopenic purpura: where do we go from here? Transfusion 2006; 46:1659.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical trials.gov identifier: NCT00799773. www.clinicaltrials.gov/ct2/results?term=NCT00799773 (Accessed on January 09, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/106\">",
"      Cataland SR, Jin M, Zheng XL, et al. An evaluation of cyclosporine alone for the treatment of early recurrences of thombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/107\">",
"      Cataland SR, Jin M, Lin S, et al. Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol 2007; 139:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/108\">",
"      Yilmaz M, Eskazan AE, Unsal A, et al. Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature. Transfusion 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/109\">",
"      B&ouml;hm M, Betz C, Miesbach W, et al. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 2005; 129:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/110\">",
"      O'Connor NT, Bruce-Jones P, Hill LF. Vincristine therapy for thrombotic thrombocytopenic purpura. Am J Hematol 1992; 39:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/111\">",
"      Ziman A, Mitri M, Klapper E, et al. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution's experience and review of the literature. Transfusion 2005; 45:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/112\">",
"      Wong P, Itoh K, Yoshida S. Treatment of thrombotic thrombocytopenic purpura with intravenous gamma globulin. N Engl J Med 1986; 314:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/113\">",
"      Booth KK, Terrell DR, Vesely SK, George JN. Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol 2011; 86:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/114\">",
"      Kanj NA, Mikati AR, Kfoury Baz EM. Early relapse of thrombotic thrombocytopenic purpura during therapeutic plasma exchange associated with Acinetobacter anitratus bacteremia. Ther Apher Dial 2003; 7:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/115\">",
"      Creager AJ, Brecher ME, Bandarenko N. Thrombotic thrombocytopenic purpura that is refractory to therapeutic plasma exchange in two patients with occult infection. Transfusion 1998; 38:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/116\">",
"      Niv E, Segev A, Ellis MH. Staphylococcus aureus bacteremia as a cause of early relapse of thrombotic thrombocytopenic purpura. Transfusion 2000; 40:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/117\">",
"      Cserti CM, Landaw S, Uhl L. Do infections provoke exacerbations and relapses of thrombotic thrombocytopenic purpura? J Clin Apher 2007; 22:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/118\">",
"      Douglas KW, Pollock KG, Young D, et al. Infection frequently triggers thrombotic microangiopathy in patients with preexisting risk factors: a single-institution experience. J Clin Apher 2010; 25:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/119\">",
"      Remuzzi G, Galbusera M, Salvadori M, et al. Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. Kidney Int 1996; 49:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/120\">",
"      Feldman M, Bruno T, Chong YC, et al. Bilateral nephrectomy for treatment resistant systemic lupus erythematosis and thrombotic thrombocytopenic purpura: a case report. Am J Hematol 2007; 82:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/121\">",
"      Kn&ouml;bl P, Jilma B, Gilbert JC, et al. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion 2009; 49:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/122\">",
"      Ruggenenti P, Galbusera M, Cornejo RP, et al. Thrombotic thrombocytopenic purpura: evidence that infusion rather than removal of plasma induces remission of the disease. Am J Kidney Dis 1993; 21:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/123\">",
"      Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med 1995; 122:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/124\">",
"      Zhan H, Streiff MB, King KE, Segal JB. Thrombotic thrombocytopenic purpura at the Johns Hopkins Hospital from 1992 to 2008: clinical outcomes and risk factors for relapse. Transfusion 2010; 50:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/125\">",
"      Jin M, Casper TC, Cataland SR, et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol 2008; 141:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/126\">",
"      Barbot J, Costa E, Guerra M, et al. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol 2001; 113:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/127\">",
"      Sivakumaran M, Roland J. Prophylactic treatment with fresh-frozen plasma in chronic thrombotic thrombocytopenic purpura. Br J Haematol 2002; 117:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/128\">",
"      Loirat C, Veyradier A, Girma JP, et al. Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children. Semin Thromb Hemost 2006; 32:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/129\">",
"      George JN. Congenital thrombotic thrombocytopenic purpura: Lessons for recognition and management of rare syndromes. Pediatr Blood Cancer 2008; 50:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/130\">",
"      Crowther MA, Heddle N, Hayward CP, et al. Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura. Ann Intern Med 1996; 125:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/131\">",
"      May HV Jr, Harbert GM Jr, Thornton WN Jr. Thrombotic thrombocytopenic purpura associated with pregnancy. Am J Obstet Gynecol 1976; 126:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/132\">",
"      Mokrzycki MH, Rickles FR, Kaplan AA, Kohn OF. Thrombotic thrombocytopenic purpura in pregnancy: successful treatment with plasma exchange. Case report and review of the literature. Blood Purif 1995; 13:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/133\">",
"      Egerman RS, Witlin AG, Friedman SA, Sibai BM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in pregnancy: review of 11 cases. Am J Obstet Gynecol 1996; 175:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/134\">",
"      McCrae KR, Cines DB. Thrombotic microangiopathy during pregnancy. Semin Hematol 1997; 34:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/135\">",
"      Natelson EA, White D. Recurrent thrombotic thrombocytopenic purpura in early pregnancy: effect of uterine evacuation. Obstet Gynecol 1985; 66:54S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/136\">",
"      Ezra Y, Rose M, Eldor A. Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: a clinical study of 16 pregnancies. Am J Hematol 1996; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/137\">",
"      Wurzei JM. TTP lesions in placenta but not fetus. N Engl J Med 1979; 301:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/138\">",
"      Dashe JS, Ramin SM, Cunningham FG. The long-term consequences of thrombotic microangiopathy (thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) in pregnancy. Obstet Gynecol 1998; 91:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/139\">",
"      Raman R, Yang S, Wu HM, Cataland SR. ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy. Br J Haematol 2011; 153:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/140\">",
"      Scully M, Starke R, Lee R, et al. Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagul Fibrinolysis 2006; 17:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/141\">",
"      Vesely SK, Li X, McMinn JR, et al. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2004; 44:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/142\">",
"      Benjamin M, Terrell DR, Vesely SK, et al. Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clin Infect Dis 2009; 48:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/143\">",
"      Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998; 128:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/144\">",
"      Bennett CL, Davidson CJ, Raisch DW, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999; 159:2524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/145\">",
"      Loirat C, Fr&eacute;meaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011; 6:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/146\">",
"      Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/147\">",
"      K&ouml;se O, Zimmerhackl LB, Jungraithmayr T, et al. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost 2010; 36:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/148\">",
"      Benhamou Y, Assi&eacute; C, Boelle PY, et al. Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica 2012; 97:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/149\">",
"      Rose M, Rowe JM, Eldor A. The changing course of thrombotic thrombocytopenic purpura and modern therapy. Blood Rev 1993; 7:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/150\">",
"      Groot E, Fijnheer R, Sebastian SA, et al. The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission. J Thromb Haemost 2009; 7:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/151\">",
"      Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109:2815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/152\">",
"      Howard MA, Duvall D, Terrell DR, et al. A support group for patients who have recovered from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): The six-year experience of the Oklahoma TTP-HUS Study Group. J Clin Apher 2003; 18:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/153\">",
"      Ambadwar P, Duvall D, Wolf NJ, et al. Support groups for patients who have recovered from thrombotic thrombocytopenic purpura. J Clin Apher 2008; 23:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/154\">",
"      Kennedy AS, Lewis QF, Scott JG, et al. Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion 2009; 49:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/155\">",
"      Lewis QF, Lanneau MS, Mathias SD, et al. Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura. Transfusion 2009; 49:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/156\">",
"      Cataland SR, Scully MA, Paskavitz J, et al. Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. Am J Hematol 2011; 86:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/157\">",
"      Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med 2001; 135:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/158\">",
"      Forzley BR, Sontrop JM, Macnab JJ, et al. Treating TTP/HUS with plasma exchange: a single centre's 25-year experience. Br J Haematol 2008; 143:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/31/42490/abstract/159\">",
"      Lotta LA, Mariani M, Consonni D, et al. Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. Br J Haematol 2010; 151:488.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1344 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-071942397F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_31_42490=[""].join("\n");
var outline_f41_31_42490=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H44\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DISEASE OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6921030\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7729522\">",
"      Plasma exchange indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Idiopathic TTP-HUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13594392\">",
"      Plasma exchange versus plasma infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13594423\">",
"      Measurement of ADAMTS13 activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22780433\">",
"      Measurement of complement levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Adult typical (diarrheal) HUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5534574\">",
"      Eculizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5534581\">",
"      Immunoadsorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Exceptions to the use of plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Platelet transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10315058\">",
"      Ineffective initial treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PLASMA EXCHANGE PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Available plasma products",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Fresh frozen plasma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Cryoprecipitate-poor plasma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Viral inactivation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Daily exchange",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3004372\">",
"      - Central catheter issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Twice-daily exchange",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10316266\">",
"      - Central venous catheter and plasma complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      POORLY RESPONSIVE, RESISTANT, OR RELAPSING DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Other immunosupressives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Treatment of concomitant infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Long-term follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87027452\">",
"      - Laboratory monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1991593\">",
"      SPECIAL SCENARIOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Relapse in subsequent pregnancies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12755683\">",
"      - Follow-up during subsequent pregnancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10315756\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Drug-induced TTP-HUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10314900\">",
"      Congenital TTP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1991633\">",
"      Atypical HUS in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22780699\">",
"      Long-term follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22780706\">",
"      - Laboratory monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22780713\">",
"      - Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107006957\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107006964\">",
"      Scoring systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107006993\">",
"      Predicting initial response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107007000\">",
"      Predicting risk of relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107007014\">",
"      Long-term outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1344\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1344|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?4/62/5088\" title=\"algorithm 1\">",
"      Algorithm management TTP-HUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1344|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/50/38694\" title=\"picture 1\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/51/22329\" title=\"picture 2A\">",
"      HUS Glomerular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/61/12246\" title=\"picture 2B\">",
"      HUS Vascular I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/49/26389\" title=\"picture 2C\">",
"      HUS Vascular II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/19/34099\" title=\"picture 2D\">",
"      HUS vascular III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/3/8255\" title=\"picture 2E\">",
"      HUS IF IV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=related_link\">",
"      Atypical hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=related_link\">",
"      Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11190?source=related_link\">",
"      Complement pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/1/29?source=related_link\">",
"      Complications of central venous catheters and their prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6646?source=related_link\">",
"      Complications of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1609?source=related_link\">",
"      Kidney disease following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44553?source=related_link\">",
"      Overview of central venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38247?source=related_link\">",
"      Pathogen inactivation of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/39/11895?source=related_link\">",
"      Preparation of blood components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/56/38793?source=related_link\">",
"      Thrombocytopenia in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30649?source=related_link\">",
"      Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_31_42491="Measures to reduce the risk and duration of postoperative ileus";
var content_f41_31_42491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Measures to reduce the risk and duration of postoperative ileus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Effective strategies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidural use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Likely effective strategies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimally-invasive surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Potentially effective strategies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonsteroidal antiinflammatory agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimally traumatic surgical techniques",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alvimopan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postoperative gum chewing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Unproven or ineffective strategies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metoclopramide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythromycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neostigmine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propanolol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ambulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delayed postoperative feeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Routine replacement of electrolytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preoperative bran diet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preoperative \"visceral learning\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coffee",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Harmful strategies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Routine use of nasogastric tubes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_31_42491=[""].join("\n");
var outline_f41_31_42491=null;
var title_f41_31_42492="Clues RD young adult";
var content_f41_31_42492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clues to dyslexia in young adults and adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Problems in speaking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistence of earlier oral language difficulties",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The mispronunciation of the names of people and places, and tripping over parts of words",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Difficulty remembering names of people and places and the confusion of names that sound alike",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A struggle to retrieve words: \"It was on the tip of my tongue\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of glibness, especially if put on the spot",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spoken vocabulary that is smaller than listening vocabulary, and hesitation to say aloud words that might be mispronounced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Problems in reading",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A childhood history of reading and spelling difficulties",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Word reading becomes more accurate over time but continues to require great effort",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of fluency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Embarrassment caused by oral reading: the avoidance of Bible study groups, reading at Passover seders, or delivering a written speech",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trouble reading and pronouncing uncommon, strange, or unique words such as people's names, street or location names, food dishes on a menu (often resorting to asking the waiter about the special of the day or resorting to saying, \"I'll have what he's having,\" to avoid the embarrassment of not being able to read the menu)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent reading problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The substitution of made-up words during reading for words that cannot be pronounced--for example,",
"        <em>",
"         metropolitan",
"        </em>",
"        becomes",
"        <em>",
"         mitan",
"        </em>",
"        --and a failure to recognize the word",
"        <em>",
"         metropolitan",
"        </em>",
"        when it is seen again or heard in a lecture the next day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extreme fatigue from reading",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Slow reading of most materials: books, manuals, subtitles in foreign films",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penalized by multiple-choice tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unusually long hours spent reading school- or work-related materials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequent sacrifice of social life for studying",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A preference for books with figures, charts, or graphics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A preference for books with fewer words per page or with lots of white showing on a page",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disinclination to read for pleasure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spelling that remains disastrous and a preference for less complicated words in writing that are easier to spell",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Particularly poor performance on rote clerical task",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shaywitz S. Overcoming Dyslexia: A New and Complete Science-Based Program for Reading Problems at Any Level. Copyright &copy; 2003 by Sally Shaywitz, M.D. Used with permission of Alfred A. Knopf, a division of Random House, Inc. For on-line information about other Random House, Inc. books and authors, see the Internet Web site at www.randomhouse.com.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_31_42492=[""].join("\n");
var outline_f41_31_42492=null;
var title_f41_31_42493="Contents: Osteoarthritis";
var content_f41_31_42493=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?3/39/3710\">",
"       Rheumatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Osteoarthritis",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Osteoarthritis",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Classification and diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/49/12056\">",
"           Clinical manifestations of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/32/33287\">",
"           Diagnosis and classification of osteoarthritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diffuse idiopathic skeletal hyperostosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/59/43960\">",
"           Diffuse idiopathic skeletal hyperostosis (DISH)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathogenesis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/42/19114\">",
"           Pathogenesis of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/43/29370\">",
"           Risk factors for and possible causes of osteoarthritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/0/26630\">",
"           Glenohumeral osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/29/9687\">",
"           Investigational approaches to the pharmacologic therapy of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/30/2538\">",
"           Nonpharmacologic therapy of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/2/40994\">",
"           Patient guidelines for weight-resistance training in osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/23/14714\">",
"           Pharmacologic therapy of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/9/12440\">",
"           Surgical therapy of osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/28/7621\">",
"           Weight-resistance exercises in patients with osteoarthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/19/5427\">",
"           Weight-resistance training in patients with osteoarthritis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-5C2F8F397F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f41_31_42493=[""].join("\n");
var outline_f41_31_42493=null;
var title_f41_31_42494="Influenza vaccines summary";
var content_f41_31_42494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Influenza vaccine information, by age group - United States, 2012-13 influenza season*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"9\" width=\"11%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vaccine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trade name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Manufacturer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Presentation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mercury content",
"        <br/>",
"        (mcg Hg/0.5 mL dose)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ovalbumin content",
"        <br/>",
"        (mcg/0.5 mL dose)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age group",
"       </td>",
"       <td class=\"subtitle1\">",
"        No. of doses",
"       </td>",
"       <td class=\"subtitle1\">",
"        Route",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        TIV",
"       </td>",
"       <td rowspan=\"4\">",
"        Fluzone",
"       </td>",
"       <td rowspan=\"4\">",
"        Sanofi Pasteur",
"       </td>",
"       <td>",
"        0.25 mL prefilled syringe",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        ---",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        6-35 mos",
"       </td>",
"       <td>",
"        1 or 2",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        IM",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.5 mL prefilled syringe",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        ---",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &ge;36 mos",
"       </td>",
"       <td>",
"        1 or 2",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        IM",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.5 mL single dose vial",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        ---",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &ge;36 mos",
"       </td>",
"       <td>",
"        1 or 2",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        IM",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5.0 mL multidose vial",
"       </td>",
"       <td>",
"        25.0",
"       </td>",
"       <td>",
"        ---",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &ge;6 mos",
"       </td>",
"       <td>",
"        1 or 2",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        IM",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        TIV",
"       </td>",
"       <td>",
"        Fluarix",
"       </td>",
"       <td>",
"        GlaxoSmithKline",
"       </td>",
"       <td>",
"        0.5 mL prefilled syringe",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &le;0.05",
"       </td>",
"       <td>",
"        &ge;3 yrs",
"       </td>",
"       <td>",
"        1 or 2",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        IM",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        TIV",
"       </td>",
"       <td rowspan=\"2\">",
"        Fluvirin",
"       </td>",
"       <td rowspan=\"2\">",
"        Novartis Vaccines",
"       </td>",
"       <td>",
"        0.5 mL prefilled syringe",
"       </td>",
"       <td>",
"        &le;1",
"       </td>",
"       <td>",
"        &le;1",
"       </td>",
"       <td rowspan=\"2\">",
"        &ge;4 yrs",
"       </td>",
"       <td rowspan=\"2\">",
"        1 or 2",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        IM",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5.0 mL multidose vial",
"       </td>",
"       <td>",
"        25.0",
"       </td>",
"       <td>",
"        &le;1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        TIV",
"       </td>",
"       <td rowspan=\"2\">",
"        Afluria",
"       </td>",
"       <td rowspan=\"2\">",
"        CSL Biotherapies (distributed by Merck)",
"       </td>",
"       <td>",
"        0.5 mL prefilled syringe",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        &le;1",
"       </td>",
"       <td rowspan=\"2\">",
"        &ge;9 yrs",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        IM",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5.0 mL multidose vial",
"       </td>",
"       <td>",
"        24.5",
"       </td>",
"       <td>",
"        &le;1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        TIV",
"       </td>",
"       <td>",
"        Agriflu",
"       </td>",
"       <td>",
"        Novartis Vaccines",
"       </td>",
"       <td>",
"        0.5 mL prefilled syringe",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        &lt;0.4",
"       </td>",
"       <td>",
"        &ge;18 yrs",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        IM",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        TIV",
"       </td>",
"       <td>",
"        FluLaval",
"       </td>",
"       <td>",
"        ID Biomedical Corporation of Quebec (distributed by GlaxoSmithKline)",
"       </td>",
"       <td>",
"        5.0 mL multidose vial",
"       </td>",
"       <td>",
"        &lt;25.0",
"       </td>",
"       <td>",
"        &le;0.3",
"       </td>",
"       <td>",
"        &ge;18 yrs",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        IM",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        TIV",
"       </td>",
"       <td>",
"        Flucelvax",
"       </td>",
"       <td>",
"        Novartis Vaccines",
"       </td>",
"       <td>",
"        0.5 mL prefilled syringe",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        none",
"       </td>",
"       <td>",
"        &ge;18 yrs",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        IM",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        TIV",
"       </td>",
"       <td>",
"        Flublok",
"       </td>",
"       <td>",
"        Protein Sciences Corporation",
"       </td>",
"       <td>",
"        0.5 mL single dose vial",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        none",
"       </td>",
"       <td>",
"        18-49 yrs",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        IM",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        TIV intradermal",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        Fluzone Intradermal",
"       </td>",
"       <td>",
"        Sanofi Pasteur",
"       </td>",
"       <td>",
"        0.1 mL prefilled microinjection system",
"       </td>",
"       <td>",
"        0.0 (per 0.1 mL)",
"       </td>",
"       <td>",
"        ---",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        18-64 yrs",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        ID",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        TIV high-dose",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        Fluzone High-Dose",
"       </td>",
"       <td>",
"        Sanofi Pasteur",
"       </td>",
"       <td>",
"        0.5 mL prefilled syringe",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"       <td>",
"        ---",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &ge;65 yrs",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        IM",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        LAIV",
"       </td>",
"       <td>",
"        FluMist**",
"       </td>",
"       <td>",
"        MedImmune",
"       </td>",
"       <td>",
"        0.2 mL prefilled intranasal sprayer",
"       </td>",
"       <td>",
"        0.0 (per 0.2 mL)",
"       </td>",
"       <td>",
"        &lt;0.24 (per 0.2 mL)",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2-49 yrs",
"        <sup>",
"         &Delta;&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        1 or 2",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        IN",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TIV: trivalent inactivated vaccine; LAIV: live attenuated influenza vaccine; IM: intramuscular; ID: intradermal; IN: intranasal.",
"     <br/>",
"     * Vaccination providers should consult US Food and Drug Administration-approved prescribing information for 2012-2013 influenza vaccines for the most updated information, including indications, contraindications, and precautions.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Data on maximum ovalbumin content are supplied in package inserts of certain vaccines. Persons with a history of mild allergy to egg (specifically, those who experience only hives) should receive TIV with additional precautions. (Refer to UpToDate topic on influenza vaccination in individuals with egg allergy.)",
"     <br/>",
"     &Delta; Information is not included in package insert but is available upon request from the manufacturer, Sanofi Pasteur, by telephone, 1-800-822-2463, or e-mail,",
"     <a href=\"mailto:MIS.Emails@sanofipasteur.com\" target=\"_blank\">",
"      MIS.Emails@sanofipasteur.com",
"     </a>",
"     .",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Refer to UpToDate topic on seasonal influenza vaccination in children for details of the schedule for children six months through eight years.",
"     <br/>",
"     &sect; For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh.",
"     <br/>",
"     &yen; Age indication per package insert is &ge;5 years; however, the Centers for Disease Control Advisory Committee on Immunization Practices recommends Afluria not be used in children aged six months through eight years because of increased risk for febrile reactions noted in this age group with CSL Biotherapies' 2010 Southern Hemisphere TIV. If no other age-appropriate licensed inactivated seasonal influenza vaccine is available for a child aged five through eight years who has a medical condition that increases the child's risk for influenza complications, Afluria can be used; however, vaccination providers should discuss with the parents or caregivers the benefits and risks of influenza vaccination with Afluria before administering this vaccine. Afluria may be used in persons aged &ge;9 years.",
"     <br/>",
"     &Dagger; A 0.1-mL dose contains 9 mcg of each vaccine antigen (27 mcg total).",
"     <br/>",
"     &dagger; A 0.5-mL dose contains 60 mcg of each vaccine antigen (180 mcg total).",
"     <br/>",
"     ** A new quadrivalent formulation of FluMist was approved by the US Food and Drug Administration in February 2012. It is anticipated that this formulation will replace the currently available seasonal trivalent LAIV formulation for the 2013-14 season. FluMist is shipped refrigerated and stored in the refrigerator at 35&deg;F to 46&deg;F (2&deg;C to 8&deg;C) after arrival in the vaccination clinic. The dose is 0.2 mL divided equally between each nostril. Health-care providers should consult the medical record, when available, to identify children aged two through four years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be at greater risk for asthma and possibly at increased risk for wheezing after receiving LAIV, parents or caregivers of children aged two through four years should be asked: \"In the past 12 months, has a health-care provider ever told you that your child had wheezing or asthma?\" Children whose parents or caregivers answer \"yes\" to this question and children who have asthma or who had a wheezing episode noted in the medical record within the past 12 months should not receive FluMist.",
"     <br/>",
"     <span class=\"double_bullet\">",
"      &bull;&bull;",
"     </span>",
"     Insufficient data available for use of LAIV in egg-allergic persons.",
"     <br/>",
"     &Delta;&Delta; FluMist is indicated for healthy, nonpregnant persons aged 2 through 49 years. Persons who care for severely immunosuppressed persons who require a protective environment should not receive FluMist given the theoretical risk for transmission of the live-attenuated vaccine virus.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2012-2013 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61:613.",
"      </li>",
"      <li>",
"       Flucelvax prescribing information. Available at",
"       <a href=\"file://www.novartisvaccinesdirect.com/pdf/Flucelvax_PI.pdf\" target=\"_blank\">",
"        www.novartisvaccinesdirect.com/pdf/Flucelvax_PI.pdf",
"       </a>",
"       . Accessed on November 28, 2012.",
"      </li>",
"      <li>",
"       Flublok prescribing information. Available at",
"       <a href=\"file://www.prize-winner.org/FlublokInsert.pdf\" target=\"_blank\">",
"        www.prize-winner.org/FlublokInsert.pdf",
"       </a>",
"       . Accessed on January 17, 2013.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_31_42494=[""].join("\n");
var outline_f41_31_42494=null;
var title_f41_31_42495="Hyperplasia lymphoid tissue";
var content_f41_31_42495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyperplasia of lymphoid tissue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperplasia of oropharyngeal lymphoid tissue in immune deficiency.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas J Barrett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_31_42495=[""].join("\n");
var outline_f41_31_42495=null;
